@article {pmid36272444,
year = {2023},
author = {Sacks-Zimmerman, A and Bergquist, TF and Farr, EM and Cornwell, MA and Kanellopoulos, D},
title = {Rehabilitation of Neuropsychiatric Symptoms in Patients With Long COVID: Position Statement.},
journal = {Archives of physical medicine and rehabilitation},
volume = {104},
number = {2},
pages = {350-354},
pmid = {36272444},
issn = {1532-821X},
mesh = {Adult ; Humans ; Post-Acute COVID-19 Syndrome ; *COVID-19 ; Quality of Life ; *Mental Disorders ; Chronic Disease ; },
abstract = {Long COVID, a term used to describe ongoing symptoms after COVID-19 infection, parallels the course of other postviral syndromes. Neuropsychiatric symptoms of long COVID can be persistent and interfere with quality of life and functioning. Within the biopsychosocial framework of chronic illness, rehabilitation professionals can address the neuropsychiatric sequelae of long COVID. However, current practice models are not designed to address concurrent psychiatric and cognitive symptoms in adults living with long COVID. Thus, we present a biopsychosocial framework for long COVID and provide treatment strategies based on evidence from current literature of postviral chronic illness. These recommendations will guide rehabilitation professionals in identifying common neuropsychiatric symptoms in long COVID that can be targeted for intervention and addressing these symptoms via integrative interventions taking into account the biopsychosocial presentation of long COVID symptoms.},
}

Adult
Humans
Post-Acute COVID-19 Syndrome
*COVID-19
Quality of Life
*Mental Disorders
Chronic Disease

@article {pmid36178109,
year = {2024},
author = {Castelletti, S and Gervasi, S and Ballardini, E and Casasco, M and Cavarretta, E and Colivicchi, F and Contursi, M and Cuccaro, F and D'Ascenzi, F and Gazale, G and Mos, L and Nistri, S and Palmieri, V and Patrizi, G and Scorcu, M and Spampinato, A and Tiberi, M and Zito, GB and Zorzi, A and Zeppilli, P and Sciarra, L and , },
title = {The athlete after COVID-19 infection: what the scientific evidence? What to do? A position statement.},
journal = {Panminerva medica},
volume = {66},
number = {1},
pages = {63-74},
doi = {10.23736/S0031-0808.22.04723-1},
pmid = {36178109},
issn = {1827-1898},
mesh = {Humans ; *COVID-19 ; Athletes ; Exercise ; Pandemics ; *Pericarditis ; },
abstract = {The Coronavirus-19 disease (COVID-19) related pandemic have deeply impacted human health, economy, psychology and sociality. Possible serious cardiac involvement in the infection has been described, raising doubts about complete healing after the disease in many clinical settings. Moreover, there is the suspicion that the vaccines, especially those based on mRNA technology, can induce myopericarditis. Myocarditis or pericarditis related scars can represent the substrate for life-threatening arrhythmias, triggered by physical activity. A crucial point is how to evaluate an athlete after a COVID-19 infection ensuring a safe return to play without increasing the number of unnecessary disqualifications from sports competitions. The lack of conclusive scientific data significantly increases the difficulty to propose recommendations and guidelines on this topic. At the same time, the psychological and physical negative consequences of unnecessary sports restriction must be taken into account. The present document aims to provide an updated brief review of the current knowledge about the COVID-19 cardiac involvement and how to recognize it and to offer a roadmap for the management of the athletes after a COVID-19 infections, including subsequent impact on exercise recommendations. Our document exclusively refers to cardiovascular implications of the disease, but pulmonary consequences are also considered.},
}

Humans
*COVID-19
Athletes
Exercise
Pandemics
*Pericarditis

@article {pmid36117294,
year = {2022},
author = {Filipiak, KJ and Babkowski, MC and Cameli, M and Carugo, S and Ferri, C and Irisov, DB and Narkiewicz, K and Nizamov, U and Pérez de Isla, L and Tomaszuk-Kazberuk, A and Ungar, A and Gąsecka, A},
title = {TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.},
journal = {Cardiology journal},
volume = {29},
number = {5},
pages = {730-738},
pmid = {36117294},
issn = {1898-018X},
mesh = {Antihypertensive Agents/therapeutic use ; *COVID-19 ; *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control ; *Dyslipidemias/diagnosis/drug therapy/epidemiology ; Humans ; *Hypertension/diagnosis/drug therapy/epidemiology ; Lipids ; Lipoproteins ; Poland ; Proprotein Convertase 9 ; Risk Factors ; },
abstract = {Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors - if detected early enough - can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the "class effect". We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.},
}

Antihypertensive Agents/therapeutic use
*COVID-19
*Cardiovascular Diseases/diagnosis/epidemiology/prevention & control
*Dyslipidemias/diagnosis/drug therapy/epidemiology
Humans
*Hypertension/diagnosis/drug therapy/epidemiology
Lipids
Lipoproteins
Poland
Proprotein Convertase 9
Risk Factors

@article {pmid36043581,
year = {2022},
author = {Cheah, FC and Thong, MK and Zulkifli, I and Zilfalil, A and Amir Hamzah, AL and Chan, PWK and Khoo, EJ and Noran, NH},
title = {COVID-19 vaccination for children in Malaysia - A position statement by the College of Paediatrics, Academy of Medicine of Malaysia.},
journal = {The Malaysian journal of pathology},
volume = {44},
number = {2},
pages = {177-185},
pmid = {36043581},
issn = {0126-8635},
mesh = {Adolescent ; *COVID-19/prevention & control ; COVID-19 Vaccines ; Child ; Child, Preschool ; Humans ; Malaysia ; *Pediatrics ; SARS-CoV-2 ; Vaccination ; *Vaccines ; },
abstract = {The availability of COVID-19 vaccines and mass vaccination programmes in adults have significantly reduced the case attack rates and disease burden. COVID-19 vaccination successfully decreases the population at risk of infection, allowing for the safer re-opening of economies and reducing the pandemic's crippling impact on healthcare systems. However, the rapidly mutating severe acute respiratory syndrome-coronavirus-2 poses challenges in diminishing vaccine-induced immunity and vaccinating a significant proportion of adults to achieve herd immunity. These challenges necessitated adolescent vaccination. With the recent emergence of the highly transmissible Omicron variant and the increasing COVID-19 hospitalisation rates of children below 12 years old, many countries opted to also vaccinate younger children. Phase II/III clinical trials and real-world experience demonstrate that COVID-19 vaccinations are effective and safe for younger children and adolescents. Before Malaysia introduced its national COVID-19 vaccination programme for children 5-11 years old (which ran between March and June 2022), an expert advisory statement was issued by the College of Paediatrics, Academy of Medicine of Malaysia, to highlight the benefits and importance of vaccinating children. The advisory statement included clarifications about vaccine-related side effects such as post-vaccination myocarditis and allergic reactions to encourage informed decision making by healthcare providers and parents. This paper, which was prepared based on the critical appraisal of the current evidence, evaluation of the international experiences and the positive impact of COVID-19 vaccination in children, collectively sums up the rationale to support and ensure the success of the nationwide vaccination programme for children. Hence, the College recommends COVID-19 vaccination for children in Malaysia.},
}

Adolescent
*COVID-19/prevention & control
COVID-19 Vaccines
Child
Child, Preschool
Humans
Malaysia
*Pediatrics
SARS-CoV-2
Vaccination
*Vaccines

@article {pmid35970790,
year = {2022},
author = {Feng, LZ and Jiang, HY and Yi, J and Qian, LL and Xu, JD and Zheng, LB and Ma, ZB and Peng, SJ and Jiang, ST and Xu, EF and Chen, LH and Wang, LD and Gao, WZ and Yang, W},
title = {[Introduction and implications of WHO position paper: vaccines against influenza, May 2022].},
journal = {Zhonghua yi xue za zhi},
volume = {102},
number = {30},
pages = {2315-2318},
doi = {10.3760/cma.j.cn112137-20220518-01090},
pmid = {35970790},
issn = {0376-2491},
support = {2021-RC330-002//Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences/ ; INV-023808/GATES/Bill & Melinda Gates Foundation/United States ; },
mesh = {*COVID-19 ; Humans ; *Influenza Vaccines ; *Influenza, Human/epidemiology/prevention & control ; SARS-CoV-2 ; World Health Organization ; },
abstract = {On May 13, 2022, World Health Organization(WHO) Position Paper on Influenza Vaccine (2022 edition) was published. This position paper updates information on influenza epidemiology, high risk population, the impact of immunization on disease, influenza vaccines and effectiveness and safety, and propose WHO's position and recommendation that all countries should consider implementing seasonal influenza vaccine immunization programmes to prepare for an influenza pandemic. In addition, it proposes that the influenza surveillance platform can be integrated with the surveillance of other respiratory viruses, such as SARS-CoV-2 and Respiratory Syncytial Virus. This position paper has some implications for the prevention and control of influenza and other respiratory infectious diseases in China: (1) Optimize influenza vaccine policies to facilitate the implementation of immunization services; (2) Influenza prevention and control should from the perspective of Population Medicine focus on the individual and community to integrate with "Promotion, Prevention, Diagnosis, Control, Treatment, Rehabilitation"; (3) Incorporate prevention and control of other respiratory infectious diseases such as influenza, COVID-19, respiratory syncytial virus and adenovirus, and intelligently monitor by integrating multi-channel data to achieve the goal of co-prevention and control of multiple diseases.},
}

*COVID-19
Humans
*Influenza Vaccines
*Influenza, Human/epidemiology/prevention & control
SARS-CoV-2
World Health Organization

@article {pmid35921761,
year = {2022},
author = {Beretta, GD and Casolino, R and Corsi, DC and Perrone, F and Di Maio, M and Cinieri, S and Gobber, G and Bellani, M and Petrini, F and Zocchi, MT and Traclò, F and Zagonel, V and , and , and , and , and , and , },
title = {Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement.},
journal = {ESMO open},
volume = {7},
number = {4},
pages = {100538},
pmid = {35921761},
issn = {2059-7029},
mesh = {*COVID-19 ; Ecosystem ; Humans ; *Medical Oncology ; Neoplasms ; Pandemics ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has severely affected cancer care and research by disrupting the prevention and treatment paths as well as the preclinical, clinical, and translational research ecosystem. In Italy, this has been particularly significant given the severity of the pandemic's impact and the intrinsic vulnerabilities of the national health system. However, whilst detrimental, disruption can also be constructive and may stimulate innovation and progress. The Italian Association of Medical Oncology (AIOM) has recognized the impact of COVID-19 on cancer care continuum and research and proposes the '2021 Matera statement' which aims at providing pragmatic guidance for policymakers and health care institutions to mitigate the impact of the global health crisis on Italian oncology and design the recovery plan for the post-pandemic scenario. The interventions are addressed both to the pillars (prevention, diagnosis, treatment, follow-up, health care professionals) and foundations of cancer care (communication and care relationship, system organization, resources, research, networking). The priorities to be implemented can be summarized in the MATERA acronym: Multidisciplinarity; Access to cancer care; Telemedicine and Territoriality; Equity, ethics, education; Research and resources; Alliance between stakeholders and patients.},
}

*COVID-19
Ecosystem
Humans
*Medical Oncology
Neoplasms
Pandemics

@article {pmid35868584,
year = {2022},
author = {Marjot, T and Eberhardt, CS and Boettler, T and Belli, LS and Berenguer, M and Buti, M and Jalan, R and Mondelli, MU and Moreau, R and Shouval, D and Berg, T and Cornberg, M},
title = {Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.},
journal = {Journal of hepatology},
volume = {77},
number = {4},
pages = {1161-1197},
pmid = {35868584},
issn = {1600-0641},
support = {102176/B/13/Z/WT_/Wellcome Trust/United Kingdom ; },
mesh = {*COVID-19 ; Humans ; *Liver Diseases/epidemiology/surgery ; *Liver Transplantation ; *Neoplasms ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic has presented a serious challenge to the hepatology community, particularly healthcare professionals and patients. While the rapid development of safe and effective vaccines and treatments has improved the clinical landscape, the emergence of the omicron variant has presented new challenges. Thus, it is timely that the European Association for the Study of the Liver provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation, as the world continues to deal with the consequences of the COVID-19 pandemic.},
}

*COVID-19
Humans
*Liver Diseases/epidemiology/surgery
*Liver Transplantation
*Neoplasms
Pandemics
SARS-CoV-2

@article {pmid35816710,
year = {2022},
author = {Crowley, R and Atiq, O and Hilden, D and , },
title = {Long-Term Services and Supports for Older Adults: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {175},
number = {8},
pages = {1172-1174},
doi = {10.7326/M22-0864},
pmid = {35816710},
issn = {1539-3704},
mesh = {Aged ; *Assisted Living Facilities ; *COVID-19/epidemiology ; Humans ; Long-Term Care ; Pandemics ; *Physicians ; United States ; },
abstract = {The number of Americans aged 65 years or older is expected to increase in the coming decades. Because the risk for disability increases with age, more persons will need long-term services and supports (LTSS) to help with bathing, eating, dressing, and other everyday tasks. Long-term services and supports are delivered in nursing homes, assisted living facilities, the person's home, and other settings. However, the LTSS sector faces several challenges, including keeping patients and staff safe during the COVID-19 pandemic, workforce shortages, quality problems, and fragmented coverage options. In this position paper, the American College of Physicians offers policy recommendations on LTSS coverage, financing, workforce, safety and quality, and emergency preparedness and calls on policymakers and other stakeholders to reform and improve the LTSS sector so that care is high quality, accessible, equitable, and affordable.},
}

Aged
*Assisted Living Facilities
*COVID-19/epidemiology
Humans
Long-Term Care
Pandemics
*Physicians
United States

@article {pmid35759767,
year = {2022},
author = {Serchen, J and Atiq, O and Hilden, D and , },
title = {Strengthening Food and Nutrition Security to Promote Public Health in the United States: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {175},
number = {8},
pages = {1170-1171},
doi = {10.7326/M22-0390},
pmid = {35759767},
issn = {1539-3704},
mesh = {*COVID-19/epidemiology ; Child ; Humans ; Pandemics/prevention & control ; *Physicians ; Poverty ; Public Health ; United States ; },
abstract = {Food insecurity functions as a social driver of health, directly negatively impacting health status and outcomes, which can further negatively impact employment and income and increase medical expenditures-all of which exacerbates food insecurity. Progress in meaningfully reducing the food-insecurity rate has stalled in recent years. Although rates have decreased since their peak during the Great Recession, these gains have been reversed by the economic implications of the COVID-19 pandemic. As the federal government is the largest provider of food assistance, there is much potential in better leveraging nutrition assistance programs like the Supplemental Nutrition Assistance Program (SNAP) and the Child Nutrition Programs to increase access to healthful foods and improve public health. However, these programs face many funding challenges and internal shortcomings that create uncertainties and prevent maximal effect. Physicians and other medical professionals also have a role in improving nutritional health by screening for food insecurity and serving as connectors between patients, community organizations, and government services. Governments and payers must support these efforts by providing sufficient resources to practices to fulfill this role. In this position paper, the American College of Physicians (ACP) offers several policy recommendations to strengthen the federal food-insecurity response and empower physicians and other medical professionals to better address those social drivers of health occurring beyond the office doors.},
}

*COVID-19/epidemiology
Child
Humans
Pandemics/prevention & control
*Physicians
Poverty
Public Health
United States

@article {pmid35715014,
year = {2022},
author = {Kohan, L and Pellis, Z and Provenzano, DA and Pearson, ACS and Narouze, S and Benzon, HT},
title = {American Society of Regional Anesthesia and Pain Medicine contrast shortage position statement.},
journal = {Regional anesthesia and pain medicine},
volume = {47},
number = {9},
pages = {511-518},
doi = {10.1136/rapm-2022-103830},
pmid = {35715014},
issn = {1532-8651},
mesh = {*Anesthesia, Conduction ; Humans ; Pain ; Pain Management ; *Physicians ; Societies, Medical ; United States ; },
abstract = {The medical field has been experiencing numerous drug shortages in recent years. The most recent shortage to impact the field of interventional pain medicine is that of iodinated contrast medium. Pain physicians must adapt to these changes while maintaining quality of care. This position statement offers guidance on adapting to the shortage.},
}

*Anesthesia, Conduction
Humans
Pain
Pain Management
*Physicians
Societies, Medical
United States

@article {pmid35692364,
year = {2022},
author = {Kaap-Fröhlich, S and Ulrich, G and Wershofen, B and Ahles, J and Behrend, R and Handgraaf, M and Herinek, D and Mitzkat, A and Oberhauser, H and Scherer, T and Schlicker, A and Straub, C and Waury Eichler, R and Wesselborg, B and Witti, M and Huber, M and Bode, SFN},
title = {Position paper of the GMA Committee Interprofessional Education in the Health Professions - current status and outlook.},
journal = {GMS journal for medical education},
volume = {39},
number = {2},
pages = {Doc17},
pmid = {35692364},
issn = {2366-5017},
mesh = {*COVID-19/epidemiology ; Curriculum ; Health Occupations ; Humans ; *Interprofessional Education ; Pandemics ; },
abstract = {In the wake of local initiatives and developmental funding programs, interprofessionality is now included in national curricula in the German-speaking countries. Based on the 3P model (presage, process, product), this position paper presents the development of interprofessional education in recent years in Germany, Austria and Switzerland and places it in an international context. Core aspects as legal frameworks, including amendments to occupational regulations as well as the formation of networks and faculty development are basic requirements for interprofessional education. New topics and educational settings take shape in the process of interprofessional education: patient perspectives and teaching formats, such as online courses, become more important or are newly established. The influence of the COVID-19 pandemic on interprofessional education is explored as well. Among many new interprofessional courses, particularly the implementation of interprofessional training wards in Germany and Switzerland are positive examples of successful interprofessional education. The objective of interprofessional education continues to be the acquisition of interprofessional competencies. The main focus is now centered on evaluating this educational format and testing for the corresponding competencies. In the future, more capacities will be required for interprofessional continuing education and post-graduate education. Structured research programs are essential to ascertain the effects of interprofessional education in the German-speaking countries. In this position paper the GMA committee on interprofessional education encourages further advancement of this topic and expresses the aim to continue cooperating with other networks to strengthen and intensify interprofessional education and collaboration in healthcare.},
}

*COVID-19/epidemiology
Curriculum
Health Occupations
Humans
*Interprofessional Education
Pandemics

@article {pmid35579481,
year = {2022},
author = {Khan, NA and Stergiou, GS and Omboni, S and Kario, K and Renna, N and Chapman, N and McManus, RJ and Williams, B and Parati, G and Konradi, A and Islam, SM and Itoh, H and Mooi, CS and Green, BB and Cho, MC and Tomaszewski, M},
title = {Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.},
journal = {Journal of hypertension},
volume = {40},
number = {8},
pages = {1435-1448},
doi = {10.1097/HJH.0000000000003205},
pmid = {35579481},
issn = {1473-5598},
mesh = {Adult ; Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; *COVID-19 ; Humans ; *Hypertension/diagnosis/drug therapy/epidemiology ; Pandemics ; },
abstract = {The coronavirus disease 2019 pandemic caused an unprecedented shift from in person care to delivering healthcare remotely. To limit infectious spread, patients and providers rapidly adopted distant evaluation with online or telephone-based diagnosis and management of hypertension. It is likely that virtual care of chronic diseases including hypertension will continue in some form into the future. The purpose of the International Society of Hypertension's (ISH) position paper is to provide practical guidance on the virtual management of hypertension to improve its diagnosis and blood pressure control based on the currently available evidence and international experts' opinion for nonpregnant adults. Virtual care represents the provision of healthcare services at a distance with communication conducted between healthcare providers, healthcare users and their circle of care. This statement provides consensus guidance on: selecting blood pressure monitoring devices, accurate home blood pressure assessments, delivering patient education virtually, health behavior modification, medication adjustment and long-term virtual monitoring. We further provide recommendations on modalities for the virtual assessment and management of hypertension across the spectrum of resource availability and patient ability.},
}

Adult
Blood Pressure
Blood Pressure Monitoring, Ambulatory
*COVID-19
Humans
*Hypertension/diagnosis/drug therapy/epidemiology
Pandemics

@article {pmid35533736,
year = {2022},
author = {Burns, SP and Fleming, TK and Webb, SS and Kam, ASH and Fielder, JDP and Kim, GJ and Hu, X and Hill, MT and Kringle, EA},
title = {Stroke Recovery During the COVID-19 Pandemic: A Position Paper on Recommendations for Rehabilitation.},
journal = {Archives of physical medicine and rehabilitation},
volume = {103},
number = {9},
pages = {1874-1882},
pmid = {35533736},
issn = {1532-821X},
support = {K23 HL159240/HL/NHLBI NIH HHS/United States ; },
mesh = {*COVID-19/epidemiology ; Communicable Disease Control ; Humans ; Pandemics ; *Stroke/epidemiology ; *Stroke Rehabilitation ; },
abstract = {Health care delivery shifted and adapted with the COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2. Stroke care was negatively affected across the care continuum and may lead to poor community living outcomes in those who survived a stroke during the ongoing pandemic. For instance, delays in seeking care, changes in length of stays, and shifts in discharge patterns were observed during the pandemic. Those seeking care were younger and had more severe neurologic effects from stroke. Increased strain was placed on caregivers and public health efforts, and community-wide lockdowns, albeit necessary to reduce the spread of COVID-19, had detrimental effects on treatment and recommendations to support community living outcomes. The American Congress of Rehabilitation Medicine Stroke Interdisciplinary Special Interest Group Health and Wellness Task Force convened to (1) discuss international experiences in stroke care and rehabilitation and (2) review recently published literature on stroke care and outcomes during the pandemic. Based on the findings in the literature, the task force proposes recommendations and interdisciplinary approaches at the (1) institutional and societal level; (2) health care delivery level; and (3) individual and interpersonal level spanning across the care continuum and into the community.},
}

*COVID-19/epidemiology
Communicable Disease Control
Humans
Pandemics
*Stroke/epidemiology
*Stroke Rehabilitation

@article {pmid35508059,
year = {2022},
author = {Moreira, HG and Oliveira Júnior, MT and Valdigem, BP and Martins, CN and Polanczyk, CA},
title = {Position Statement on Cardiovascular Safety of Vaccines Against COVID-19 - 2022.},
journal = {Arquivos brasileiros de cardiologia},
volume = {118},
number = {4},
pages = {789-796},
pmid = {35508059},
issn = {1678-4170},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; *Cardiovascular System ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
*Cardiovascular System
Humans
SARS-CoV-2
*Vaccines

@article {pmid35460319,
year = {2022},
author = {Rakusa, M and Öztürk, S and Moro, E and Helbok, R and Bassetti, CL and Beghi, E and Bereczki, D and Bodini, B and Di Liberto, G and Jenkins, TM and Macerollo, A and Maia, LF and Martinelli-Boneschi, F and Pisani, A and Priori, A and Sauerbier, A and Soffietti, R and Taba, P and von Oertzen, TJ and Zedde, M and Crean, M and Burlica, A and Cavallieri, F and Sellner, J and , },
title = {COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.},
journal = {European journal of neurology},
volume = {29},
number = {8},
pages = {2163-2172},
pmid = {35460319},
issn = {1468-1331},
mesh = {*COVID-19/complications/prevention & control ; *COVID-19 Vaccines/administration & dosage ; Humans ; *Nervous System Diseases ; Pandemics ; SARS-CoV-2 ; Vaccination/psychology ; *Vaccination Hesitancy ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND AND PURPOSE: Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course.

METHODS: In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation.

RESULTS: The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction.

CONCLUSIONS: The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.},
}

*COVID-19/complications/prevention & control
*COVID-19 Vaccines/administration & dosage
Humans
*Nervous System Diseases
Pandemics
SARS-CoV-2
Vaccination/psychology
*Vaccination Hesitancy
Post-Acute COVID-19 Syndrome

@article {pmid35434988,
year = {2022},
author = {Parthasaradhi, A and Ganguly, S and Kar, BR and Thomas, J and Neema, S and Tahiliani, S and Sathishkumar, D and Parasramani, SG and Chalam, KV and Komeravalli, H},
title = {Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).},
journal = {Indian journal of dermatology, venereology and leprology},
volume = {88},
number = {3},
pages = {286-290},
doi = {10.25259/IJDVL_773_2021},
pmid = {35434988},
issn = {0973-3922},
mesh = {*COVID-19/epidemiology/prevention & control ; COVID-19 Vaccines ; Humans ; India/epidemiology ; *Psoriasis/diagnosis/drug therapy/epidemiology ; SARS-CoV-2 ; Vaccination ; *Vaccines ; },
abstract = {Coronavirus disease 2019 (COVID-19) pandemic has affected every sphere of life including management of psoriasis. The availability of COVID-19 vaccines has given rise to hope and at the same time some apprehensions as well. With the general population becoming eligible for vaccination, there is some confusion, on the eligibility of patients with different medical conditions and patients on immunosuppressive or immunomodulating medications for COVID-19 vaccination. Dermatologists treating psoriasis patients frequently face questions from them, whether they can undergo coronavirus disease 2019 vaccination. A PUBMED search was performed using the following strategy: 'COVID-19' AND 'Vaccine' AND 'Psoriasis'. We also performed a PUBMED search using the following strategy: 'SARS-CoV-2' AND 'Vaccine' AND 'Psoriasis'. All articles irrespective of language and publication date were included to arrive at this position statement. This position statement deals with the safety, eligibility and modifications of treatment, if needed among psoriasis patients with regards to the coronavirus disease 2019 vaccines currently available in India.},
}

*COVID-19/epidemiology/prevention & control
COVID-19 Vaccines
Humans
India/epidemiology
*Psoriasis/diagnosis/drug therapy/epidemiology
SARS-CoV-2
Vaccination
*Vaccines

@article {pmid35343485,
year = {2021},
author = {Violini, R and De Rosa, S and Leonardi, S and Doronzo, B and Cremonesi, A and Callea, G and Spandonaro, F and Tarantini, G and Esposito, G and Cernetti, C and Indolfi, C and Berti, S and Marchese, A and Saia, F and Monti, F},
title = {[GISE (Italian Society of Interventional Cardiology) Position paper: Short-term hospitalization for percutaneous coronary intervention; a helpful tool to manage post-COVID-19 backlogs].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {12 Suppl 2},
pages = {4-15},
doi = {10.1714/3723.37134},
pmid = {35343485},
issn = {1972-6481},
mesh = {*COVID-19 ; *Cardiology ; Hospitalization ; Humans ; Length of Stay ; Pandemics/prevention & control ; *Percutaneous Coronary Intervention/adverse effects ; },
abstract = {Minimization of hospital lengths of stay has always been a key goal for healthcare systems. More so during the current COVID-19 pandemic. In fact, we have faced a reduction in no-COVID-19 admissions with the generation of huge backlogs. Low-risk patients undergoing elective percutaneous coronary intervention (PCI) can be candidate for short-term hospitalization, with consequent reduction of waiting lists. Several single-center and multicenter observational studies, multiple randomized trials and some meta-analyses have addressed this topic.In this position paper, we present a proposal for short hospitalization for elective PCI procedures in selected patients who present complications only exceptionally and exclusively immediately after the procedure, if the inclusion and exclusion criteria are met. Each Center can choose between admission in day surgery or one day surgery, extending hospital length of stay only for patients who present complications or who are candidate for urgent surgery. Short-term hospitalization considerably reduces costs even if, with the current model, it generally results in a parallel reduction in reimbursement. Hence, we present an actual model, already tested successfully in an Italian hospital, that warrants sustainability. This approach can then be tailored to single Centers.},
}

*COVID-19
*Cardiology
Hospitalization
Humans
Length of Stay
Pandemics/prevention & control
*Percutaneous Coronary Intervention/adverse effects

@article {pmid35240931,
year = {2022},
author = {Kwasnicka, D and Keller, J and Perski, O and Potthoff, S and Ten Hoor, GA and Ainsworth, B and Crutzen, R and Dohle, S and van Dongen, A and Heino, M and Henrich, JF and Knox, L and König, LM and Maltinsky, W and McCallum, C and Nalukwago, J and Neter, E and Nurmi, J and Spitschan, M and Van Beurden, SB and Van der Laan, LN and Wunsch, K and Levink, JJJ and Sanderman, R},
title = {White Paper: Open Digital Health - accelerating transparent and scalable health promotion and treatment.},
journal = {Health psychology review},
volume = {16},
number = {4},
pages = {475-491},
doi = {10.1080/17437199.2022.2046482},
pmid = {35240931},
issn = {1743-7202},
mesh = {Humans ; *Pandemics/prevention & control ; *COVID-19 ; Health Promotion ; Global Health ; },
abstract = {In this White Paper, we outline recommendations from the perspective of health psychology and behavioural science, addressing three research gaps: (1) What methods in the health psychology research toolkit can be best used for developing and evaluating digital health tools? (2) What are the most feasible strategies to reuse digital health tools across populations and settings? (3) What are the main advantages and challenges of sharing (openly publishing) data, code, intervention content and design features of digital health tools? We provide actionable suggestions for researchers joining the continuously growing Open Digital Health movement, poised to revolutionise health psychology research and practice in the coming years. This White Paper is positioned in the current context of the COVID-19 pandemic, exploring how digital health tools have rapidly gained popularity in 2020-2022, when world-wide health promotion and treatment efforts rapidly shifted from face-to-face to remote delivery. This statement is written by the Directors of the not-for-profit Open Digital Health initiative (n = 6), Experts attending the European Health Psychology Society Synergy Expert Meeting (n = 17), and the initiative consultant, following a two-day meeting (19-20th August 2021).},
}

Humans
*Pandemics/prevention & control
*COVID-19
Health Promotion
Global Health

@article {pmid35112371,
year = {2022},
author = {Barbaud, A and Garvey, LH and Arcolaci, A and Brockow, K and Mori, F and Mayorga, C and Bonadonna, P and Atanaskovic-Markovic, M and Moral, L and Zanoni, G and Pagani, M and Soria, A and Jošt, M and Caubet, JC and Carmo, A and Mona, AA and Alvarez-Perea, A and Bavbek, S and Benedetta, B and Bilo, MB and Blanca-López, N and Bogas, HG and Buonomo, A and Calogiuri, G and Carli, G and Cernadas, J and Cortellini, G and Celik, G and Demir, S and Doña, I and Dursun, AB and Eberlein, B and Faria, E and Fernandes, B and Garcez, T and Garcia-Nunez, I and Gawlik, R and Gelincik, A and Gomes, E and Gooi, JHC and Grosber, M and Gülen, T and Hacard, F and Hoarau, C and Janson, C and Johnston, SL and Joerg, L and Kepil Özdemir, S and Klimek, L and Košnik, M and Kowalski, ML and Kuyucu, S and Kvedariene, V and Laguna, JJ and Lombardo, C and Marinho, S and Merk, H and Meucci, E and Morisset, M and Munoz-Cano, R and Murzilli, F and Nakonechna, A and Popescu, FD and Porebski, G and Radice, A and Regateiro, FS and Röckmann, H and Romano, A and Sargur, R and Sastre, J and Scherer Hofmeier, K and Sedláčková, L and Sobotkova, M and Terreehorst, I and Treudler, R and Walusiak-Skorupa, J and Wedi, B and Wöhrl, S and Zidarn, M and Zuberbier, T and Agache, I and Torres, MJ},
title = {Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.},
journal = {Allergy},
volume = {77},
number = {8},
pages = {2292-2312},
doi = {10.1111/all.15241},
pmid = {35112371},
issn = {1398-9995},
mesh = {*Anaphylaxis/diagnosis ; *COVID-19/prevention & control ; *COVID-19 Vaccines/adverse effects ; *Drug Hypersensitivity/diagnosis/etiology/therapy ; Humans ; *Vaccines ; Vaccines, Synthetic ; mRNA Vaccines ; },
abstract = {BACKGROUND: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized.

METHOD: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed.

RESULTS: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1-anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2-anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine; and 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable.

CONCLUSIONS: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.},
}

*Anaphylaxis/diagnosis
*COVID-19/prevention & control
*COVID-19 Vaccines/adverse effects
*Drug Hypersensitivity/diagnosis/etiology/therapy
Humans
*Vaccines
Vaccines, Synthetic
mRNA Vaccines

@article {pmid35103926,
year = {2022},
author = {Cosentini, R and Groff, P and Brambilla, AM and Camajori Todeschini, R and Gangitano, G and Ingrassia, S and Marino, R and Nori, F and Pagnozzi, F and Panero, F and Ferrari, R and , },
title = {SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia.},
journal = {Internal and emergency medicine},
volume = {17},
number = {4},
pages = {1175-1189},
pmid = {35103926},
issn = {1970-9366},
mesh = {*COVID-19/complications/therapy ; *Emergency Medicine ; Humans ; *Noninvasive Ventilation/methods ; Respiration, Artificial ; *Respiratory Insufficiency ; SARS-CoV-2 ; },
abstract = {The rapid worldwide spread of the Coronavirus disease (COVID-19) crisis has put health systems under pressure to a level never experienced before, putting intensive care units in a position to fail to meet an exponentially growing demand. The main clinical feature of the disease is a progressive arterial hypoxemia which rapidly leads to ARDS which makes the use of intensive care and mechanical ventilation almost inevitable. The difficulty of health systems to guarantee a corresponding supply of resources in intensive care, together with the uncertain results reported in the literature with respect to patients who undergo early conventional ventilation, make the search for alternative methods of oxygenation and ventilation and potentially preventive of the need for tracheal intubation, such as non-invasive respiratory support techniques particularly valuable. In this context, the Emergency Department, located between the area outside the hospital and hospital ward and ICU, assumes the role of a crucial junction, due to the possibility of applying these techniques at a sufficiently early stage and being able to rapidly evaluate their effectiveness. This position paper describes the indications for the use of non-invasive respiratory support techniques in respiratory failure secondary to COVID-19-related pneumonia, formulated by the Non-invasive Ventilation Faculty of the Italian Society of Emergency Medicine (SIMEU) on the base of what is available in the literature and on the authors' direct experience. Rationale, literature, tips & tricks, resources, risks and expected results, and patient interaction will be discussed for each one of the escalating non-invasive respiratory techniques: standard oxygen, HFNCO, CPAP, NIPPV, and awake self-repositioning. The final chapter describes our suggested approach to the failing patient.},
}

*COVID-19/complications/therapy
*Emergency Medicine
Humans
*Noninvasive Ventilation/methods
Respiration, Artificial
*Respiratory Insufficiency
SARS-CoV-2

@article {pmid34973937,
year = {2022},
author = {Manzano-Aquiahuatl, C and Tobar-Fredes, R and Zavala-Solares, MR and Salle-Levy, D and Imamura, R and Morales-Fernández, R and Ojeda-Peña, L and Parra-Reyes, D and Santoro, P and Ton, V and Trujillo-Benavides, OE and Vargas-García, MA and Furkim, AM},
title = {Position statement of the Latin American Dysphagia Society for the management of oropharyngeal and esophageal dysphagia during the COVID-19 pandemic.},
journal = {Revista de gastroenterologia de Mexico (English)},
volume = {87},
number = {1},
pages = {63-79},
pmid = {34973937},
issn = {2255-534X},
mesh = {*COVID-19 ; *Deglutition Disorders/epidemiology/therapy ; Humans ; Latin America/epidemiology ; Pandemics ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: The SARS-CoV-2 virus that causes the COVID-19 disease is transmitted through the inhalation of droplets or aerosols and inoculation via the oronasal or ocular routes, transforming the management of swallowing disorders into a challenge for healthcare teams, given their proximity to the aerodigestive tract and the high probability of aerosol generation during patient evaluation and treatment.

AIM: To provide essential guidance for Latin American multidisciplinary teams, regarding the evaluation and treatment of oropharyngeal and esophageal dysphagia, at the different levels of healthcare. The position statement was formulated for the purpose of maintaining medical service continuity, in the context of a pandemic, and minimizing the propagation and infection risks of the virus.

METHODS: Thirteen experts in swallowing disorders were summoned by the Latin American Dysphagia Society to formulate a series of clinical suggestions, based on available evidence and clinical experience, for the management of dysphagia, taking the characteristics of Latin American healthcare systems into account.

RESULTS: The position statement of the Latin American Dysphagia Society provides a series of clinical suggestions directed at the multidisciplinary teams that manage patients with oropharyngeal and esophageal dysphagia. It presents guidelines for evaluation and treatment in different contexts, from hospitalization to home care.

CONCLUSIONS: The present statement should be analyzed by each team or healthcare professional, to reduce the risk for COVID-19 infection and achieve the best therapeutic results, while at the same time, being mindful of the reality of each Latin American country.},
}

*COVID-19
*Deglutition Disorders/epidemiology/therapy
Humans
Latin America/epidemiology
Pandemics
SARS-CoV-2

@article {pmid34933373,
year = {2022},
author = {Gralnek, IM and Hassan, C and Ebigbo, A and Fuchs, A and Beilenhoff, U and Antonelli, G and Bisschops, R and Arvanitakis, M and Bhandari, P and Bretthauer, M and Kaminski, MF and Lorenzo-Zuniga, V and Rodriguez de Santiago, E and Siersema, PD and Tham, TC and Triantafyllou, K and Tringali, A and Voiosu, A and Webster, G and de Pater, M and Fehrke, B and Gazic, M and Gjergek, T and Maasen, S and Waagenes, W and Dinis-Ribeiro, M and Messmann, H},
title = {ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants.},
journal = {Endoscopy},
volume = {54},
number = {2},
pages = {211-216},
doi = {10.1055/a-1700-4897},
pmid = {34933373},
issn = {1438-8812},
mesh = {*COVID-19 ; Endoscopy, Gastrointestinal ; *Gastroenterology ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*COVID-19
Endoscopy, Gastrointestinal
*Gastroenterology
Humans
SARS-CoV-2
*Vaccines

@article {pmid34915764,
year = {2021},
author = {Wang, X and Gkrouzman, E and Andrade, DCO and Andreoli, L and Barbhaiya, M and Belmont, HM and Branch, DW and de Jesús, GR and Efthymiou, M and Ríos-Garcés, R and Gerosa, M and El Hasbani, G and Knight, J and Meroni, PL and Pazzola, G and Petri, M and Rand, J and Salmon, J and Tektonidou, M and Tincani, A and Uthman, IW and Zuily, S and Zuo, Y and Lockshin, M and Cohen, H and Erkan, D and , },
title = {COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).},
journal = {Lupus},
volume = {30},
number = {14},
pages = {2276-2285},
pmid = {34915764},
issn = {1477-0962},
support = {R01 AR069572/AR/NIAMS NIH HHS/United States ; },
mesh = {*Antibodies, Antiphospholipid ; *Antiphospholipid Syndrome ; *COVID-19/pathology ; Humans ; *Thrombosis/virology ; },
abstract = {Coronavirus disease 2019 (COVID-19) is associated with a high rate of thrombosis. Prolonged activated partial thromboplastin times (aPTT) and antiphospholipid antibodies (aPL) are reported in COVID-19 patients. The majority of publications have not reported whether patients develop clinically relevant persistent aPL, and the clinical significance of new aPL-positivity in COVID-19 is currently unknown. However, the reports of aPL-positivity in COVID-19 raised the question whether common mechanisms exist in the pathogenesis of COVID-19 and antiphospholipid syndrome (APS). In both conditions, thrombotic microangiopathy resulting in microvascular injury and thrombosis is hypothesized to occur through multiple pathways, including endothelial damage, complement activation, and release of neutrophil extracellular traps (NETosis). APS-ACTION, an international APS research network, created a COVID-19 working group that reviewed common mechanisms, positive aPL tests in COVID-19 patients, and implications of COVID-19 infection for patients with known aPL positivity or APS, with the goals of proposing guidance for clinical management and monitoring of aPL-positive COVID-19 patients. This guidance also serves as a call and focus for clinical and basic scientific research.},
}

*Antibodies, Antiphospholipid
*Antiphospholipid Syndrome
*COVID-19/pathology
Humans
*Thrombosis/virology

@article {pmid34855691,
year = {2022},
author = {Keder, RD and Mittal, S and Stringer, K and Wallis, KE and Wallace, JE and Soares, NS},
title = {Society for Developmental & Behavioral Pediatrics Position Statement on Telehealth.},
journal = {Journal of developmental and behavioral pediatrics : JDBP},
volume = {43},
number = {1},
pages = {55-59},
doi = {10.1097/DBP.0000000000001046},
pmid = {34855691},
issn = {1536-7312},
mesh = {*COVID-19 ; Humans ; Pandemics ; *Pediatrics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Telehealth has long held promise as a way to increase access to subspecialty care for children and families, including in developmental and behavioral pediatrics (DBP). The coronavirus disease 2019 (COVID-19) pandemic necessitated rapid uptake of telehealth to continue care delivery that was facilitated by "temporary" policy changes related to the pandemic. As a result, the field of DBP has recognized telehealth as a potential model of care for performing home-based diagnostic assessments, providing medication management follow-up, and delivering therapeutic interventions for children with neurodevelopmental disorders. Telehealth has been helpful in mitigating barriers families often face when attending in-person visits (lack of transportation and child care, missed work hours, etc) but has also highlighted additional determinants of health that need to be addressed to provide equitable access to care (broadband connectivity, device access, digital literacy, access to interpretation and sign language services, etc). Anticipating the lifting of pandemic-related emergency declaration and expiration of temporary policies around telehealth, the ability to continue to deliver DBP care by telehealth is uncertain. The purpose of this policy statement is to advocate for legislation and policies that support ongoing, equitable, home-based telehealth care for patients seen by DBP providers while ensuring equitable access to DBP in general. In addition, there is a need to recognize the benefits and challenges of telehealth versus in-person care and to identify clinical scenarios that favor 1 model of care versus the other.},
}

*COVID-19
Humans
Pandemics
*Pediatrics
SARS-CoV-2
*Telemedicine

@article {pmid34845404,
year = {2021},
author = {Curcio, A and Spaccarotella, C and Brunetti, ND and Molinari, G and Carugo, S and Basso, C and Ciccone, MM and Filardi, PP and Mancone, M and Mercuro, G and Muscoli, S and Nodari, S and Pedrinelli, R and Barillà, F and Sinagra, G and Indolfi, C},
title = {[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {12},
pages = {1017-1023},
doi = {10.1714/3698.36881},
pmid = {34845404},
issn = {1972-6481},
mesh = {Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; *COVID-19 ; *Cardiology ; Electrocardiography, Ambulatory ; Humans ; Pandemics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {The current COVID-19 pandemic has renewed interest in providing healthcare services based on the implementation of innovative technologies. Such strategy capillarizes the therapeutic opportunities for larger urban areas, mostly when people are living under extraordinarily difficult circumstances. Improving care delivery in cardiovascular diseases appears particularly feasible when telemedicine is pursued, especially with regard to baseline standard 12-lead electrocardiography, ambulatory electrocardiographic monitoring, and 24-hour ambulatory blood pressure monitoring. Nowadays, these first-line cardiovascular examinations are also available in health centers and pharmacies, and in recent months, there has been an increasing demand of such local services in the absence of specific rules and regulations regarding technical requirements and standards of interpretation that ensure a high quality clinical consultation.The purpose of this position paper is to provide critical requirements for the type/model of devices to be used, training dedicated to healthcare personnel, ensuring security of sensitive data, highlighting type of platforms to be used, as well as for maintaining high reporting quality and standards.},
}

Blood Pressure
Blood Pressure Monitoring, Ambulatory
*COVID-19
*Cardiology
Electrocardiography, Ambulatory
Humans
Pandemics
SARS-CoV-2
*Telemedicine

@article {pmid34841822,
year = {2021},
author = {Latif, A and Faull, C and Waring, J and Wilson, E and Anderson, C and Avery, A and Pollock, K},
title = {Managing medicines at the end of life: a position paper for health policy and practice.},
journal = {Journal of health organization and management},
volume = {35},
number = {9},
pages = {368-377},
pmid = {34841822},
issn = {1758-7247},
mesh = {*COVID-19 ; Death ; Health Policy ; Humans ; *Pandemics ; SARS-CoV-2 ; },
abstract = {PURPOSE: The impact of population ageing is significant, multifaceted and characterised by frailty and multi-morbidity. The COVID-19 pandemic has accelerated care pathways and policies promoting self-management and home-based care. One under-researched area is how patients and family caregivers manage the complexity of end-of-life therapeutic medicine regimens. In this position paper the authors bring attention to the significant strain that patients and family caregivers experience when navigating and negotiating this aspect of palliative and end-of-life care.

DESIGN/METHODOLOGY/APPROACH: Focussing on self-care and organisation of medicines in the United Kingdom (UK) context, the paper examines, builds on and extends the debate by considering the underlying policy assumptions and unintended consequences for individual patients and family care givers as they assume greater palliative and end-of-life roles and responsibilities.

FINDINGS: Policy makers and healthcare professionals often lack awareness of the significant burden and emotional work associated with managing and administering often potent high-risk medicines (i.e. opioids) in the domiciliary setting. The recent "revolution" in professional roles associated with the COVID-19 pandemic, including remote consultations and expanding community-based care, means there are opportunities for commissioners to consider offering greater support. The prospect of enhancing the community pharmacist's medicine optimisation role to further support the wider multi-disciplinary team is considered.

ORIGINALITY/VALUE: The paper takes a person-focused perspective and adopts a holistic view of medicine management. The authors argue for urgent review, reform and investment to enable and support terminally ill patients and family caregivers to more effectively manage medicines in the domiciliary setting. There are clear implications for pharmacists and these are discussed in the context of public awareness, inter-professional collaboration, organisational drivers, funding and regulation and remote care delivery.},
}

*COVID-19
Death
Health Policy
Humans
*Pandemics
SARS-CoV-2

@article {pmid34810293,
year = {2022},
author = {Bharadva, K and Bellad, RM and Tiwari, S and Somasekar, R and Phadke, M and Bodhankar, U and Bang, A and Kinikar, AA and Mallikarjuna, HB and Shah, J and Khurana, O and Gunasingh, D and Basavaraja, GV and Kumar, R and Gupta, P},
title = {Breastfeeding in Coronavirus Disease 2019 (COVID-19): Position Statement of Indian Academy of Pediatrics and Infant and Young Child Feeding Chapter.},
journal = {Indian pediatrics},
volume = {59},
number = {1},
pages = {58-62},
pmid = {34810293},
issn = {0974-7559},
mesh = {Breast Feeding ; *COVID-19 ; Child ; Female ; Humans ; Infant ; Pandemics ; *Pediatrics ; SARS-CoV-2 ; },
abstract = {JUSTIFICATION: Recent research has provided evidence for lack of transmission of SARS-CoV-2 through human milk and breastfeeding. Updating the practice guidelines will help in providing appropriate advice and support regarding breastfeeding during the coronavirus 2019 (COVID-19) pandemic.

OBJECTIVES: To provide evidence-based guidelines to help the healthcare professionals to advise optimal breastfeeding practices during the COVID-19 pandemic.

PROCESS: Formulation of key questions was done under the chairmanship of President of the IAP. It was followed by review of literature and the recommendations of other international and national professional bodies. Through Infant and Young child (IYCF) focused WhatsApp group opinion of all members was taken. The final document was prepared after the consensus and approval by all members of the committee.

RECOMMENDATIONS: The IYCF Chapter of IAP strongly recommends unabated promotion, protection and support to breastfeeding during the COVID-19 pandemic with due precautions.},
}

Breast Feeding
*COVID-19
Child
Female
Humans
Infant
Pandemics
*Pediatrics
SARS-CoV-2

@article {pmid34711104,
year = {2022},
author = {Pandian, JD and Panagos, PD and Sebastian, IA and Sampaio Silva, G and Furie, KL and Liu, L and Owolabi, MO and Caso, V and Alrukn, SA},
title = {Maintaining stroke care during the COVID-19 pandemic in lower- and middle-income countries: World Stroke Organization Position Statement endorsed by American Stroke Association and American Heart Association.},
journal = {International journal of stroke : official journal of the International Stroke Society},
volume = {17},
number = {1},
pages = {9-17},
pmid = {34711104},
issn = {1747-4949},
support = {D43 TW012030/TW/FIC NIH HHS/United States ; R01 NS107900/NS/NINDS NIH HHS/United States ; R01 NS115944/NS/NINDS NIH HHS/United States ; U54 HG007479/HG/NHGRI NIH HHS/United States ; },
mesh = {American Heart Association ; *COVID-19 ; Developing Countries ; Humans ; Pandemics ; SARS-CoV-2 ; *Stroke/epidemiology/therapy ; United States/epidemiology ; },
abstract = {For more than a year, the SARS-CoV-2 pandemic has had a devastating effect on global health. High-, low-, and middle-income countries are struggling to cope with the spread of newer mutant strains of the virus. Delivery of acute stroke care remains a priority despite the pandemic. In order to maintain the time-dependent processes required to optimize delivery of intravenous thrombolysis and endovascular therapy, most countries have reorganized infrastructure to optimize human resources and critical services. Low-and-middle income countries (LMIC) have strained medical resources at baseline and often face challenges in the delivery of stroke systems of care (SSOC). This position statement aims to produce pragmatic recommendations on methods to preserve the existing SSOC during COVID-19 in LMIC and propose best stroke practices that may be low cost but high impact and commonly shared across the world.},
}

American Heart Association
*COVID-19
Developing Countries
Humans
Pandemics
SARS-CoV-2
*Stroke/epidemiology/therapy
United States/epidemiology

@article {pmid34694269,
year = {2022},
author = {Nicastro, E and Ebel, NH and Kehar, M and Czubkowski, P and Ng, VL and Michaels, MG and Lobritto, SJ and Martinez, M and Indolfi, G},
title = {The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases: A Joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation Position Paper.},
journal = {Journal of pediatric gastroenterology and nutrition},
volume = {74},
number = {1},
pages = {159-170},
pmid = {34694269},
issn = {1536-4801},
mesh = {*COVID-19/complications ; Child ; *Gastroenterology ; Humans ; *Liver Diseases ; *Liver Transplantation ; RNA, Viral ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome ; },
abstract = {Children are seldom affected by severe forms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2) infection; however, the impact of comorbidities in the clinical presentation and outcome of SARS-CoV2 in children is poorly characterized including that of chronic liver disease (CLD) and those taking immunosuppressive medications for autoimmune liver disease or following liver transplantation (LT). Although not the main target organ, a spectrum of liver involvement has been described in children infected with SARS-CoV2 and those presenting with Multisystem Inflammatory Syndrome in Children (MIS-C). The Hepatology Committee of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the Society of Pediatric Liver Transplantation (SPLIT) present an evidence-based position paper on liver involvement in children with SARS-CoV2 infection and its impact on those with CLD as well as LT recipients. All children may exhibit acute liver injury from SARS-CoV2 infection, and those with CLD and may experience hepatic decompensation. Preventative and therapeutic measures are discussed.},
}

*COVID-19/complications
Child
*Gastroenterology
Humans
*Liver Diseases
*Liver Transplantation
RNA, Viral
SARS-CoV-2
Systemic Inflammatory Response Syndrome

@article {pmid34692391,
year = {2021},
author = {, and Ferat, LR and Forrest, R and Sehmi, K and Santos, RD and Stewart, D and Boulton, AJM and Jiménez, BY and Riley, P and Burger, D and Jones, ESW and Tomaszewski, M and Milanese, MR and Laffin, P and Jha, V and Borisch, B and Moore, M and Pinto, FJ and Piñeiro, D and Eiselé, JL and Lackland, DT and Whelton, PK and Zhang, XH and Stavdal, A and Li, D and Hobbs, R and Pandian, JD and Brainin, M and Feigin, V},
title = {Preventing the Next Pandemic: The Case for Investing in Circulatory Health - A Global Coalition for Circulatory Health Position Paper.},
journal = {Global heart},
volume = {16},
number = {1},
pages = {66},
pmid = {34692391},
issn = {2211-8179},
mesh = {Aged ; Humans ; *COVID-19 ; Global Health ; *Noncommunicable Diseases/epidemiology/prevention & control ; Pandemics/prevention & control ; SARS-CoV-2 ; },
abstract = {The Coronavirus Disease 2019 (COVID-19) has had a continuous and robust impact on world health. The resulting COVID-19 pandemic has had a devastating physical, mental and fiscal impact on the millions of people living with noncommunicable diseases (NCDs). In addition to older age, people living with CVD, stroke, obesity, diabetes, kidney disease, and hypertension are at a particularly greater risk for severe forms of COVID-19 and its consequences. Meta-analysis indicates that hypertension, diabetes, chronic kidney disease, and thrombotic complications have been observed as both the most prevalent and most dangerous co-morbidities in COVID-19 patients. And despite the nearly incalculable physical, mental, emotional, and economic toll of this pandemic, forthcoming public health figures continue to place cardiovascular disease as the number one cause of death across the globe in the year 2020. The world simply cannot wait for the next pandemic to invest in NCDs. Social determinants of health cannot be addressed only through the healthcare system, but a more holistic multisectoral approach with at its basis the Sustainable Development Goals (SDGs) is needed to truly address social and economic inequalities and build more resilient systems. Yet there is reason for hope: the 2019 UN Political Declaration on UHC provides a strong framework for building more resilient health systems, with explicit calls for investment in NCDs and references to fiscal policies that put such investment firmly within reach. By further cementing the importance of addressing circulatory health in a future Framework Convention on Emergency Preparedness, WHO Member States can take concrete steps towards a pandemic-free future. As the chief representatives of the global circulatory health community and patients, the Global Coalition for Circulatory Health calls for increased support for the healthcare workforce, global vaccine equity, embracing new models of care and digital health solutions, as well as fiscal policies on unhealthy commodities to support these investments.},
}

Aged
Humans
*COVID-19
Global Health
*Noncommunicable Diseases/epidemiology/prevention & control
Pandemics/prevention & control
SARS-CoV-2

@article {pmid34620212,
year = {2021},
author = {Venturini, E and Montagnani, C and Garazzino, S and Donà, D and Pierantoni, L and Lo Vecchio, A and Krzysztofiak, A and Nicolini, G and Bianchini, S and Galli, L and Villani, A and Gattinara, GC and , },
title = {Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper.},
journal = {Italian journal of pediatrics},
volume = {47},
number = {1},
pages = {199},
pmid = {34620212},
issn = {1824-7288},
mesh = {COVID-19/epidemiology/*therapy ; Child ; *Disease Management ; Female ; Humans ; *Infectious Disease Medicine ; Italy ; Male ; *Periodicals as Topic ; Practice Guidelines as Topic ; *SARS-CoV-2 ; *Societies, Medical ; },
}

COVID-19/epidemiology/*therapy
Child
*Disease Management
Female
Humans
*Infectious Disease Medicine
Italy
Male
*Periodicals as Topic
Practice Guidelines as Topic
*SARS-CoV-2
*Societies, Medical

@article {pmid34612556,
year = {2021},
author = {Rosano, G and Jankowska, EA and Ray, R and Metra, M and Abdelhamid, M and Adamopoulos, S and Anker, SD and Bayes-Genis, A and Belenkov, Y and Gal, TB and Böhm, M and Chioncel, O and Cohen-Solal, A and Farmakis, D and Filippatos, G and González, A and Gustafsson, F and Hill, L and Jaarsma, T and Jouhra, F and Lainscak, M and Lambrinou, E and Lopatin, Y and Lund, LH and Milicic, D and Moura, B and Mullens, W and Piepoli, MF and Ponikowski, P and Rakisheva, A and Ristic, A and Savarese, G and Seferovic, P and Senni, M and Thum, T and Tocchetti, CG and Van Linthout, S and Volterrani, M and Coats, AJS},
title = {COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.},
journal = {European journal of heart failure},
volume = {23},
number = {11},
pages = {1806-1818},
pmid = {34612556},
issn = {1879-0844},
mesh = {Aged ; *COVID-19 ; COVID-19 Vaccines ; *Cardiology ; Frail Elderly ; *Heart Failure ; Humans ; *Iron Deficiencies ; SARS-CoV-2 ; Vaccination ; },
abstract = {Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.},
}

Aged
*COVID-19
COVID-19 Vaccines
*Cardiology
Frail Elderly
*Heart Failure
Humans
*Iron Deficiencies
SARS-CoV-2
Vaccination

@article {pmid34570120,
year = {2021},
author = {Di Tano, G and Di Lenarda, A and Iacoviello, M and Oliva, F and Urbinati, S and Aspromonte, N and Cipriani, M and Caldarola, P and Murrone, A and Gulizia, MM and Colivicchi, F and Gabrielli, D},
title = {[ANMCO Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {10},
pages = {854-860},
doi = {10.1714/3666.36517},
pmid = {34570120},
issn = {1972-6481},
mesh = {Aminobutyrates ; Angiotensin Receptor Antagonists ; Biphenyl Compounds ; *COVID-19 ; Drug Combinations ; *Heart Failure/drug therapy ; Humans ; Pandemics ; Prospective Studies ; SARS-CoV-2 ; Stroke Volume ; Tetrazoles ; Treatment Outcome ; Valsartan ; },
abstract = {Sacubitril/valsartan (S/V) has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in chronic heart failure with reduced ejection fraction compared to enalapril. After 7 years since the publication of the results of PARADIGM-HF, further insight has been gained with potential new indications. Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. Furthermore, some studies have highlighted the favorable effects of S/V in attenuating adverse myocardial remodeling, supporting an early benefit after treatment. Observational data from non-randomized studies in AHF report that in-hospital and pre-discharge prescription of evidence-based drugs associated with better survival still remains suboptimal. Additionally, the COVID-19 pandemic has also negatively impacted on outpatient activities. Therefore, hospitalization, a real crossroads in the history of heart failure, must become a management and therapeutic opportunity for our patients. The objective of this ANMCO position paper is to encourage and facilitate early S/V administration in stabilized patients during hospitalization after an AHF episode, with the aim of improving care efficiency and clinical outcome.},
}

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
*COVID-19
Drug Combinations
*Heart Failure/drug therapy
Humans
Pandemics
Prospective Studies
SARS-CoV-2
Stroke Volume
Tetrazoles
Treatment Outcome
Valsartan

@article {pmid34570114,
year = {2021},
author = {Bisceglia, I and Gabrielli, D and Canale, ML and Gallucci, G and Parrini, I and Turazza, FM and Russo, G and Maurea, N and Quagliariello, V and Lestuzzi, C and Oliva, S and Di Fusco, SA and Lucà, F and Tarantini, L and Trambaiolo, P and Gulizia, MM and Colivicchi, F},
title = {[ANMCO Position paper: Cardio-oncology in the COVID-19 era].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {10},
pages = {800-825},
doi = {10.1714/3666.36511},
pmid = {34570114},
issn = {1972-6481},
mesh = {*COVID-19 ; Humans ; *Myocardial Infarction ; *Neoplasms/therapy ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic and its impact on patients with cancer and cardiovascular disease have confirmed the particular vulnerability of this population. Indeed, not only a higher risk of contracting the infection has been reported, but also an increased occurrence of a more severe course and unfavorable outcome. Beyond the direct consequences of COVID-19, the pandemic has an enormous impact on global health systems. Screening programs and non-urgent tests have been postponed; clinical trials have suffered a setback. Similarly, in the area of cardiology care, a significant decline in ST-elevation myocardial infarction accesses and an increase in cases of late presenting heart attacks with increased mortality and complication rates have been reported. Health care systems must therefore get ready to tackle the "rebound effect" that will likely show a relative increase in the short and medium term incidence of diseases such as heart failure, myocardial infarction, arrhythmias and cardio- and cerebrovascular complications. Scientific societies are taking action to provide general guidance and recommendations aimed at mitigating the unfavorable outcomes of this pandemic emergency. Cardio-oncology, as an emerging discipline, is more flexible in modulating care pathways and represents a beacon of innovation in the development of multi-specialty patient management. In the era of the COVID-19 pandemic, cardio-oncology has rapidly modified its clinical care pathways and implemented flexible monitoring protocols that include targeted use of cardiac imaging, increased use of biomarkers, and telemedicine systems. The goal of these strategic adjustments is to minimize the risk of infection for providers and patients while maintaining standards of care for the treatment of oncologic and cardiovascular diseases. The aim of this position paper is to evaluate the impact of the COVID-19 pandemic on the management of cardio-oncologic patients with the-state-of-the-art knowledge about SARS-CoV-2 and COVID-19 in order to optimize medical strategies during and after the pandemic.},
}

*COVID-19
Humans
*Myocardial Infarction
*Neoplasms/therapy
Pandemics
SARS-CoV-2

@article {pmid34561208,
year = {2021},
author = {Sánchez-Álvarez, E and Quiroga, B and de Sequera, P and , },
title = {Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.},
journal = {Nefrologia},
volume = {41},
number = {4},
pages = {412-416},
pmid = {34561208},
issn = {2013-2514},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; *Nephrology ; RNA, Messenger ; SARS-CoV-2 ; *Vaccines ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide over the last year causing more than one million deaths. Several treatments have tried to modify the natural history of the coronavirus disease 2019 (COVID-19) but only corticosteroids have demonstrated to be effective in moderate or severe affectation. In that situation, the development of vaccines for preventing the SARS-CoV-2 infection has focused the attention of the scientific community. At present, available messenger RNA-based technology vaccines have received the approval of local and international sanitary authorities. In this position statement, the Spanish Society of Nephrology wants to state that patients with chronic kidney disease and healthcare workers are at high-risk for contagion and complications of COVID-19 so they must have priority in the vaccine administration.},
}

*COVID-19/prevention & control
COVID-19 Vaccines
Humans
*Nephrology
RNA, Messenger
SARS-CoV-2
*Vaccines

@article {pmid34532923,
year = {2022},
author = {Testino, G and Vignoli, T and Patussi, V and Allosio, P and Amendola, MF and Aricò, S and Baselice, A and Balbinot, P and Campanile, V and Fanucchi, T and Macciò, L and Meneguzzi, C and Mioni, D and Parisi, M and Renzetti, D and Rossin, R and Gandin, C and Bottaro, LC and Caio, G and Lungaro, L and Zoli, G and Scafato, E and Caputo, F},
title = {Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA).},
journal = {Addiction biology},
volume = {27},
number = {1},
pages = {e13090},
pmid = {34532923},
issn = {1369-1600},
mesh = {Alcoholics Anonymous ; Alcoholism/epidemiology/*therapy ; Ambulatory Care/organization & administration ; COVID-19/epidemiology/*prevention & control ; COVID-19 Vaccines/therapeutic use ; *Communicable Disease Control ; Delivery of Health Care/organization & administration ; Disease Susceptibility ; Drug Interactions ; Humans ; Immunosuppression Therapy/adverse effects ; Italy/epidemiology ; Liver Cirrhosis, Alcoholic/epidemiology/therapy ; Liver Transplantation ; Recurrence ; SARS-CoV-2 ; Societies, Medical ; Telemedicine ; COVID-19 Drug Treatment ; },
abstract = {Coronavirus disease 2019 (COVID-19) first emerged in China in November 2019. Most governments have responded to the COVID-19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID-19 era (group activities, telemedicine, outpatients treatment, alcohol-related liver disease and liver transplantation, collecting samples); (d) AUD and SARS-CoV-2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID-19 disease will need implementation. Thus, the COVID-19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in-depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment.},
}

Alcoholics Anonymous
Alcoholism/epidemiology/*therapy
Ambulatory Care/organization & administration
COVID-19/epidemiology/*prevention & control
COVID-19 Vaccines/therapeutic use
*Communicable Disease Control
Delivery of Health Care/organization & administration
Disease Susceptibility
Drug Interactions
Humans
Immunosuppression Therapy/adverse effects
Italy/epidemiology
Liver Cirrhosis, Alcoholic/epidemiology/therapy
Liver Transplantation
Recurrence
SARS-CoV-2
Societies, Medical
Telemedicine
COVID-19 Drug Treatment

@article {pmid41379358,
year = {2025},
author = {Gomes, P and de Menêses, AG and Silveira, RCCP and Guerra, ENS and Dos Reis, PED and Ferreira, EB},
title = {Radiation recall dermatitis in cancer patients previously undergoing radiotherapy: a scoping review.},
journal = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
volume = {34},
number = {1},
pages = {26},
pmid = {41379358},
issn = {1433-7339},
mesh = {Humans ; *Radiodermatitis/etiology/epidemiology ; *Neoplasms/radiotherapy/drug therapy ; Antineoplastic Agents/adverse effects/administration & dosage ; Female ; Radiotherapy/adverse effects ; },
abstract = {PURPOSE: To map the evidence related to radiation recall dermatitis (RRD) in cancer patients previously treated with radiotherapy.

METHODS: A scoping review was conducted following the methodology outlined by the JBI Collaboration. The search was performed in PubMed, CINAHL, LILACS, Scopus, Web of Science Core Collection, Cochrane, and grey literature using Google Scholar and ProQuest on January 28, 2025. Studies published in any language and without restrictions on publication year were included.

RESULTS: This review incorporated 210 studies on RRD in cancer patients, with a predominance of case reports and case series (84.7%). Approximately 48% of cases were reported in breast cancer patients. Among these studies, 92 primary articles documented 201 instances of RRD. A significant association was identified with antineoplastic agents (73.6%), predominantly due to chemotherapy, with docetaxel identified as the most frequently reported agent (13.5%). The radiotherapy doses administered ranged from 8 to 65 Grays, and the time intervals between radiotherapy and the onset of the RRD-triggering agent varied widely, from hours to 40 years. This condition can cause symptoms such as erythema, dry and moist desquamation, edema, itching, pain, ulceration, necrosis, and bleeding.

CONCLUSION: RRD is a significant adverse event, particularly among women with breast cancer, most commonly associated with chemotherapy involving docetaxel and doxorubicin. COVID-19 infection and vaccination have also been reported as potential new triggers of RRD. Further research is needed to clarify the underlying mechanisms and to optimize therapeutic strategies for at-risk patients.},
}

Humans
*Radiodermatitis/etiology/epidemiology
*Neoplasms/radiotherapy/drug therapy
Antineoplastic Agents/adverse effects/administration & dosage
Female
Radiotherapy/adverse effects

@article {pmid41379341,
year = {2025},
author = {Mahdizadeh, S and Hamid, KH and Roudsari, MB and Jamil, NY and Alfarttoosi, KH and Taher, SG and Alwan, M and Jawad, M and Mushtaq, H and Soleimani, M and Tabatabaei, SN},
title = {Impact of emerging and re-emerging viral infections on periodontitis progression.},
journal = {Archives of microbiology},
volume = {208},
number = {1},
pages = {59},
pmid = {41379341},
issn = {1432-072X},
mesh = {Humans ; *Periodontitis/virology/microbiology/pathology/immunology ; *COVID-19/complications/virology ; *Virus Diseases/virology/complications ; Disease Progression ; SARS-CoV-2 ; },
abstract = {Periodontitis is a chronic inflammatory disease that progressively destroys the tooth-supporting structures, including the gums, periodontal ligament, and alveolar bone. This destruction is primarily driven not by the bacteria themselves, but by the host's dysregulated immune response to a dysbiotic subgingival biofilm. Bacterial colonization in periodontal disease (PD) triggers both innate and adaptive immune responses. Furthermore, numerous viruses-including human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and herpes simplex virus (HSV)-have been linked to periodontal disorders and contribute to the etiopathogenesis of periodontitis alongside bacteria. Since its emergence in 2020, COVID-19 has posed a significant global health threat. SARS-CoV-2 infection within the periodontium may induce local inflammation, potentially exacerbating PDs. Given that viral replication and persistence in tissues are thought to increase with the severity of inflammation, the presence of these viruses may be linked to the development and progression of periodontitis. The current study is unique in its synthesis of data on a wide spectrum of viruses associated with periodontitis. This includes common viruses (EBV, HCMV, HSV, human papillomavirus (HPV), and human immunodeficiency virus (HIV)), emerging viruses (Chikungunya, Dengue), and novel viruses such as SARS-CoV-2. By providing a comprehensive overview of viral co-infections in periodontitis, this review advocates for the development of new antiviral diagnostic and therapeutic strategies that adopt a broad, virus-centric approach. We conducted a literature search across PubMed, Google Scholar, and Web of Science using keywords and Medical Subject Headings (MeSH) terms such as "viral infection," "periodontitis," and specific virus names.},
}

Humans
*Periodontitis/virology/microbiology/pathology/immunology
*COVID-19/complications/virology
*Virus Diseases/virology/complications
Disease Progression
SARS-CoV-2

@article {pmid41379191,
year = {2025},
author = {La Scaléa, ACR and Uehara, SCDSA},
title = {Pain in Long COVID: A scoping review of clinical characteristics and patterns of manifestation.},
journal = {Revista latino-americana de enfermagem},
volume = {33},
number = {},
pages = {e4777},
doi = {10.1590/1518-8345.7836.4777},
pmid = {41379191},
issn = {1518-8345},
mesh = {Humans ; *COVID-19/complications ; Female ; *Pain/etiology/diagnosis/epidemiology ; Male ; Pain Measurement ; SARS-CoV-2 ; },
abstract = {to map the available scientific evidence on the clinical characteristics and patterns of pain manifestation (location, frequency, duration, intensity, and quality) in individuals with Long COVID. a scoping review of publications from March 2020 to June 2024, indexed across four databases. Study selection was conducted by two independent, blinded reviewers. Data were extracted using a standardized instrument and analyzed descriptively. nineteen studies were included, indicating that pain affects individuals across all age groups, with higher prevalence among women, primarily involving the head, neck, shoulder, lower back, and hip. Pain frequency ranged from daily to monthly episodes, with duration exceeding one year in some cases. Intensity varied from mild to severe, and pain characteristics were diverse, with descriptors including burning, pressure, colicky, and throbbing pain. the clinical characteristics and patterns of pain manifestation in Long COVID are diverse. However, there is a paucity of studies providing detailed analyses of pain features and the influence of individual variables. These findings should guide future research and clinical practice toward a more comprehensive and contextualized assessment of pain in Long COVID.},
}

Humans
*COVID-19/complications
Female
*Pain/etiology/diagnosis/epidemiology
Male
Pain Measurement
SARS-CoV-2

@article {pmid41378159,
year = {2025},
author = {Mahamadou, D and Abdoul-Aziz, AB and Moustapha, LM and Alkassoum, I and Fils, SA and Hamsatou, B and Bachir, G and Abdourahmane, Y and Farouk, M and Lagare, A and Eric, A and Issifou, D and Hassane, N and Habibatou, I and Eholié, SP},
title = {Resurgence of epidemics in Zinder: effect of the decrease in vaccination coverage and the impacts of climate change.},
journal = {IJID regions},
volume = {17},
number = {},
pages = {100781},
pmid = {41378159},
issn = {2772-7076},
abstract = {OBJECTIVES: Several epidemic outbreaks have affected the Zinder region. These include diseases targeted by the expanded immunization program and other emerging diseases. This study aimed to analyze these epidemics.

METHODS: This is documentary research of the epidemics of meningitis, measles, cholera, COVID-19, and diphtheria, which occurred in the Zinder region from 2015 to 2023, as well as their determinants. The data collection is made from the linear list of notifiable diseases of the Regional Directorate of Health and Public Hygiene of Zinder, associated with literature review on the determinants of the appearance of these epidemics.

RESULTS: The number of meningitis cases has gradually increased in Zinder from 2019 to 2024. A total of 5019 cases were registered during these epidemics, with a mortality rate of 6.31%. Five measles epidemics have been recorded since 2015. A total of 13,887 cases were notified during these epidemics, with a mortality rate of 0.30%. Three cholera epidemics occurred: in 2021, in 2022, and in 2024. During these epidemics, 884 cases were recorded, with 24 deaths or a lethality of 2.71%. The COVID-19 epidemic occurred in 2020, with 364 cases, including 17 deaths, i.e. a mortality rate of 4.67%. Since 2022, the region has been facing a diphtheria epidemic. A total of 3310 cases has been reported, with 173 deaths. The causes of these epidemics are multifaceted; they involve the decline in vaccination coverage, migration, insecurity, the COVID-19 pandemic, and climate change.

CONCLUSIONS: The impact of epidemics on the health of the population and the socio-economic development of regions implies a greater mastery of the root causes mentioned in this study.},
}

@article {pmid41378119,
year = {2025},
author = {Shepherd, J and Leake, MC},
title = {Invention, innovation, and commercialisation in British biophysics.},
journal = {Biophysical reviews},
volume = {17},
number = {4},
pages = {1143-1156},
pmid = {41378119},
issn = {1867-2450},
abstract = {British biophysics has a tradition of scientific invention and innovation, resulting in new technologies transforming biological insight, such as rapid DNA sequencing, super-resolution and label-free microscopy, high-throughput and single-molecule bio-sensing, and bio-inspired synthetic materials. Some advances were established through democratised platforms and many have biomedical success, a key example involving the SARS-CoV-2 spike protein during the COVID-19 pandemic. Here, three UK labs made crucial contributions revealing how the spike protein targets human cells and how therapies of vaccines and neutralising nanobodies work, enabled largely through biophysical innovations of cryo-electron microscopy. Here, we discuss leading-edge innovations which resulted from discovery-led British "Physics of Life" research (capturing blends of physical-life sciences research in the UK including biophysics and biological physics) and have matured into wide-reaching sustainable commercial ventures enabling translational impact. We describe the biophysical science which led to these academic spinouts, presenting the scientific questions that were addressed through innovating new techniques and approaches. We consider these examples through the lens of opportunities and challenges for academic biophysics research in partnership with British industry. We highlight how commercial breakthroughs have emerged organically from fundamental research rather than from technology-first approaches but also discuss lessons to learn from past failures. Finally, we propose recommendations concerning future resourcing and structuring of UK biophysics research and the training and support of its researchers to ensure that UK plc punches above its weight in biophysics innovation and a need to educate the policymakers and public that an absence of basic science impoverishes innovation.},
}

@article {pmid41378112,
year = {2025},
author = {Mijangos, LRR and Harding, SE and Darton, NJ},
title = {Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment.},
journal = {Biophysical reviews},
volume = {17},
number = {4},
pages = {1013-1031},
pmid = {41378112},
issn = {1867-2450},
abstract = {The transition of immunotherapy administration from intravenous infusion to subcutaneous (SC) administration of monoclonal antibody formulations for oncology patients has garnered significant interest. SC administration offers multiple benefits, including potential for at-home administration, enhanced patient compliance, reduced hospital congestion, lowered health care costs, and improved sustainability by reducing drug wastage and minimizing environmental impact. However, for many biologics, the shift to SC administration requires the development of high-concentration monoclonal antibody products (HCmAP) due to the need for large dose volumes. Here we explore the impact of the COVID-19 pandemic on immunotherapy administration and the imperative of adopting SC administration. We discuss challenges encountered throughout the manufacturing, shipping, storage, and delivery of HCmAP. A central hurdle identified involves the biophysical instability and the large increase in viscosity of these biologics due to increased antibody concentration. Further complications can arise from "non-ideality" effects through molecular crowding or co-exclusion effects (macromolecules blocking the free movement in solution of other macromolecules) and elevated macromolecular interactions. For reducing the viscosity for a given concentration of antibody, the main excipients reported are salts and amino acids, with Arg-HCl demonstrating particularly improved formulation viscosity in an HCmAP. However, excipients with viscosity-lowering effects can also impact protein stability. The journey to discover suitable excipient strategies remains ongoing, combined with emerging approaches such as molecular engineering and computational techniques, with the ultimate aim of facilitating the successful integration of SC administration for economic savings, environmental sustainability, and social equity.},
}

@article {pmid41377933,
year = {2025},
author = {Yang, B and Liu, J and Li, Y and Liu, X},
title = {mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.},
journal = {Cancer innovation},
volume = {4},
number = {6},
pages = {e70041},
pmid = {41377933},
issn = {2770-9183},
abstract = {The groundbreaking success of messenger RNA (mRNA) vaccines during the COVID-19 pandemic has significantly accelerated their application in oncology. This review comprehensively synthesizes the recent advancements in mRNA cancer vaccine development, emphasizing three critical domains: mechanistic innovations, clinical translation, and ongoing challenges. Technologically, advancements in nucleotide modification, lipid nanoparticle (LNP) delivery systems, and AI-driven neoantigen selection have significantly improved vaccine stability, immunogenicity, and personalization. Clinically, more than 150 trials have demonstrated the synergistic efficacy of mRNA vaccines (e.g., mRNA-4157/V940, BNT122) in combination with immune checkpoint inhibitors (ICIs), particularly in melanoma, with Phase III trials currently underway. Individualized neoantigen vaccines targeting patient-specific mutations have shown unprecedented response rates (> 50% in certain cohorts), while shared-antigen vaccines are progressing for high-incidence cancers. However, several critical challenges remain: (1) overcoming immunosuppressive tumor microenvironments (TME), (2) addressing systemic toxicities and LNP-related limitations, (3) scaling up cost-effective personalized manufacturing, and (4) optimizing targeted delivery. Future research directions encompass self-amplifying mRNA constructs, novel biomaterial vectors, neoadjuvant applications, and multi-omics integration for next-generation vaccine development. With rapid industrialization and evolving regulatory frameworks, mRNA vaccines are well-positioned to revolutionize precision cancer immunotherapy despite persistent translational barriers.},
}

@article {pmid41377469,
year = {2025},
author = {Ali, A and Shariq, K and Ashok Kumar, K and Zakai, A and Mumtaz, K and Ali, Z and Akmal, M and Kailash, SJ},
title = {Analyzing global research trends in hepatology during Coronavirus Disease 2019: a bibliometric analysis.},
journal = {Annals of medicine and surgery (2012)},
volume = {87},
number = {12},
pages = {8376-8384},
pmid = {41377469},
issn = {2049-0801},
abstract = {OBJECTIVE: Analyzing global hepatology trends during Coronavirus Disease 2019 (COVID-19) to accelerate effective treatments and protocols for researchers and healthcare systems.

METHODS: The related papers to COVID-19 and hepatology were extracted from 2019 to 2023. The articles were ranked according to the number of citations and a final list of top 101 most-cited articles were shortlisted. Analysis was carried out on the following: total citation count, publication year, journal name and its Impact factor, gender and their H-index, country of origin, funding information, and content of the articles. Citations per year and citations per author were calculated for all articles.

RESULTS: Between 2019 and 2023, the top 101 cited articles covered various topics. The highest number were published in 2021 (n = 42), with the American Journal of Transplantation contributing the most (n = 23). The University of Pennsylvania had the most influential presence (n = 5). These articles came from 44 countries where the US ranked first with 35 articles. There were a total of 160 authors involved, with each paper having a median and mean of 6 and 7.3 authors, respectively. The articles were categorized into nine main topics, with therapeutic intervention being the most common (n = 26) followed by pathophysiology (n = 20). Males outnumbered females as first and senior authors. A majority (n = 55) received funding, and most (n = 81) did not declare conflicts of interest.

CONCLUSION: Top articles in our analysis focused on liver transplantation, pathophysiology, and healthcare management. It can aid researchers in assessing the effectiveness of different treatment modalities for hepatic impairment in COVID-19 patients.},
}

@article {pmid41377081,
year = {2025},
author = {Lin, L and Talib, MBA},
title = {Exploring the relationship between domain-specific self-efficacy and motivation among university students: a systematic review (2019-2024).},
journal = {Frontiers in psychology},
volume = {16},
number = {},
pages = {1702507},
pmid = {41377081},
issn = {1664-1078},
abstract = {The interplay between domain-specific self-efficacy and motivation in higher education has garnered significant attention, particularly in the context of challenges such as the COVID-19 pandemic that have profoundly altered the educational landscape. This study provides a systematic review of the literature on the relationship between domain-specific self-efficacy and motivation among university students, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. From an initial pool of 5,890 articles sourced from the Education Resources Information Centre (ERIC), Scopus, and Web of Science (WoS) databases, 31 studies published between 2019 and 2024 were analyzed. Our findings underscore a predominantly positive correlation between domain-specific self-efficacy and motivation. Higher levels of self-efficacy are consistently linked to increased motivation, suggesting that enhancing self-efficacy could be a crucial strategy for boosting student motivation and, thus, academic success. Notably, many studies focus on Asian regions, highlighting both the universality and cultural specificity of these findings. However, the presence of an outlier study that found no significant relationship between self-efficacy and motivation indicates the complexity of these constructs and the potential impact of situational factors, warranting further investigation. Additionally, this review reveals a growing academic interest in self-efficacy and motivation, particularly within social sciences and education. This trend underscores the importance of a multidisciplinary approach to understanding the intricate dynamics between self-efficacy and motivation. The documented rise in research attention reflects a growing recognition of the critical role that self-efficacy and motivation play in student learning outcomes. In conclusion, this systematic review not only highlights the significant positive impact of domain-specific self-efficacy on student motivation but also calls for more nuanced studies. Future research should explore under-represented contexts and examine the broader implications of these findings across diverse educational and cultural settings.},
}

@article {pmid41376972,
year = {2025},
author = {Soto-Feijóo, R and Landín, E and Martínez-Martínez, H and Carreiras, M and Fanego, A and Ferreiro, L and Rodríguez-Núñez, N and Toubes, ME and Valdés, L},
title = {Analyzing pleural fluid attributes in SARS-CoV-2 infection: a systematic review.},
journal = {Journal of thoracic disease},
volume = {17},
number = {11},
pages = {10510-10518},
pmid = {41376972},
issn = {2072-1439},
abstract = {BACKGROUND: The characteristics of pleural fluid (PF) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are poorly understood. During the pandemic, several cases of pleural effusion (PE) have been reported, but no clear conclusions have been reached regarding the features of this fluid. This systematic review aimed to analyze and summarize the available evidence on PF attributes in patients with SARS-CoV-2 infection.

METHODS: Systematic literature search using the PRISMA methodology of studies describing PF characteristics of SARS-CoV-2 patients and treatment of PE.

RESULTS: Eighteen articles (32 patients and 37 PF samples) were included. Median age was 61 years (range, 25-81 years), male/female ratio 5.4:1. PE was predominantly unilateral (71.4%), with no distinction between one side and the other; it usually extended over 2/3 of the hemithorax (50%) and its appearance was variable [serous (50%), hematic or serohematic (28.1%) and purulent (21.9%)]. PF was exudative in 88.9% of cases, but with PF protein and PF/serum protein ratio values less than 3 g/dL and 0.5 in 36.7% and 54.5%, respectively. The pH and glucose values were less than 7.20 and 60 mg/dL in 28.6% and 24% of cases, respectively. The percentage of neutrophils (≥50%) was higher than that of lymphocytes/monocytes [12/26 (46.2%) vs. 7/26 (26.9%), respectively]. Polymerase chain reaction (PCR) on PF was positive for SARS-CoV-2 in 6/23 cases (26.1%) and for other pathogens in 8 (5 bacteria and 3 fungi). Almost all patients underwent thoracentesis and the medical treatment received by the cases with positive PCR for SARS-CoV-2 on PF varied. Patient follow-up was provided in 25 cases and 10 cases died (40%).

CONCLUSIONS: PE from coronavirus disease 2019 (COVID-19) infection is more frequent among males aged 50-80 years, generally unilateral and large. Its appearance is variable, with features of lactate dehydrogenase (LDH)-discordant exudate, usually predominantly neutrophilic, with treatment like that of any other PE. PE from COVID-19 infection is a poor prognostic sign and associated with worse mortality.},
}

@article {pmid41376141,
year = {2025},
author = {Sucu, R and Erku, D and Filiniuk, O and Kohler, R},
title = {Establishing an independent HTA agency in Ukraine: a conceptual framework for governance, operations, and long-term sustainability.},
journal = {International journal of technology assessment in health care},
volume = {41},
number = {1},
pages = {e85},
doi = {10.1017/S0266462325103255},
pmid = {41376141},
issn = {1471-6348},
support = {AID-121-C-17-00004//United States Agency for International Development/ ; },
mesh = {Ukraine ; *Technology Assessment, Biomedical/organization & administration/legislation & jurisprudence ; Humans ; COVID-19/epidemiology ; SARS-CoV-2 ; Health Policy ; },
abstract = {OBJECTIVES: Health technology assessment (HTA) has become an integral part of Ukraine's health system since its formal introduction into national legislation in 2017. By 2020, HTA was mandated for evaluating publicly funded medicines, laying the groundwork for more evidence-based healthcare decisions. Although the creation of an independent HTA agency was initially planned for 2022, implementation was delayed due to the COVID-19 pandemic and Russia's ongoing invasion. The relevant Cabinet Resolution calls for the establishment of an autonomous agency by January 2026. This commentary outlines a strategic, evidence-informed framework to guide the agency's formation.

METHODS: Drawing on the 2018 State Strategy for Access to Medicines, the 2022 Law on Medicinal Products, and international best practices, we proposed to the Government of Ukraine a two-tier structure encompassing core business functions (HTA and appraisal, guideline development, pricing, and listing) and support business functions (data and analytics, finance and strategy, IT, human resources, legal, and communications). Each department is tasked with clear mandates and supported by performance indicators to promote transparency, accountability, and operational efficiency.

RESULTS: A phased roadmap for 2025-2027 details the legal, institutional, and financial steps required for successful implementation. Key opportunities - including international partnerships and system-wide reform - are weighed alongside risks such as funding uncertainty, workforce limitations, and geopolitical instability.

CONCLUSION: By embedding HTA into national policy processes and ensuring institutional independence, Ukraine can enhance the value of healthcare investments and build long-term resilience into its health system.},
}

Ukraine
*Technology Assessment, Biomedical/organization & administration/legislation & jurisprudence
Humans
COVID-19/epidemiology
SARS-CoV-2
Health Policy

@article {pmid41375836,
year = {2025},
author = {Stratulat-Chiriac, I and Țarcă, E and Chistol, RO and Halip, IA and Țarcă, V and Furnică, C},
title = {Association Between Congenital Gastrointestinal Malformation Outcome and Largely Asymptomatic SARS-CoV-2 Infection in Pediatric Patients-A Systematic Review.},
journal = {Journal of clinical medicine},
volume = {14},
number = {23},
pages = {},
doi = {10.3390/jcm14238533},
pmid = {41375836},
issn = {2077-0383},
abstract = {Objective. Limited evidence is available concerning the surgical outcomes of patients with congenital gastrointestinal malformations and perioperative SARS-CoV-2 infection. This study examines the scientific evidence on SARS-CoV-2 infection and congenital gastrointestinal malformations requiring surgery in children. Material and Methods. We performed a systematic review of studies reporting data on children with congenital gastrointestinal malformations and SARS-CoV-2 infection, published in international databases (PubMed and Embase) from pandemic inception up to August 2024. Studies not reporting data on the SARS-CoV-2 infection status on patients with congenital digestive malformation were excluded. We assessed the quality of the included studies according to the Joanna Institute (JBI) appraisal checklist, adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, and registered the protocol with the PROSPERO database (CRD42024550744). Results. From the 902 titles retrieved, eight observational studies met the inclusion criteria comprising 29 patients from countries with different socioeconomic statuses. Most patients were neonates (75%) with a median age of 3 days at diagnosis and male to female ratio of 2:1. In total, 18 (62%) presented upper gastrointestinal tract anomalies, including esophageal atresia ± tracheoesophageal fistula (n = 10, 34.48%), duodenal atresia (n = 3, 10.3%), and congenital hypertrophic pyloric stenosis (n = 5, 17.2%). Lower digestive tract malformations (11, 38%) included anorectal malformations (n = 6, 20.6%), intestinal atresia (n = 3, 10.3%), Hirschsprung disease (n = 1, 3.44%), and Meckel's diverticulum (n = 1, 3.44%). Surgeries were primarily emergency or urgent procedures and only pyloromyotomy (5/5) was consistently operated minimally invasively. SARS-CoV-2 infection was identified mainly on routine screening (>95%). Of 29 patients, 85% were discharged home, and no postoperative surgical mortality and significant complications directly associated with COVID-19 were identified, although routine postoperative morbidity not linked to SARS-CoV-2 was observed. Conclusions. Pediatric patients with congenital gastrointestinal malformationsand perioperative SARS-CoV-2 infection typically have mild illness and favorable surgical outcomes. SARS-CoV-2 positivity alone should not delay essential surgery when infection control measures are ensured. Standardized, multicenter studies are needed to clarify perioperative risks to and inform management of this high-risk group.},
}

@article {pmid41375650,
year = {2025},
author = {Watts, P and Deac, A and Netuveli, G},
title = {An Umbrella Review of Quality of Life Among the General Population During the COVID-19 Pandemic.},
journal = {Journal of clinical medicine},
volume = {14},
number = {23},
pages = {},
doi = {10.3390/jcm14238348},
pmid = {41375650},
issn = {2077-0383},
abstract = {Background/Objectives: The COVID-19 pandemic has had widespread effects on quality of life (QoL). This umbrella review aimed to synthesise review-level evidence on the impact of the COVID-19 pandemic on QoL across the general population, including children, adolescents, adults, and older people. Methods: A systematic search of databases (MEDLINE (PubMed); EBSCOHost; Scopus; Google Scholar) and review repositories was conducted to identify systematic reviews, meta-analyses, and scoping reviews published between 2019 and 2025. Eligible reviews (2019-2025, English, peer-reviewed) included narrative, systematic and meta-analytic syntheses of quantitative, qualitative or mixed-methods evidence examining the impact of the COVID-19 pandemic on quality of life in the general population, using validated QoL measures. The review followed Joanna Briggs Institute methodology for umbrella reviews, with data synthesised narratively by QoL domain and population group. Results: Nine reviews met the inclusion criteria, encompassing 272 primary studies. Most reported declines in QoL across psychological, physical, and social domains. Children and adolescents experienced reductions in emotional and social functioning. Working-age adults reported psychological strain linked to economic and health-related stressors, while older adults were vulnerable to isolation and reduced social QoL. Environmental and structural factors also influenced QoL. Sociodemographic disparities were observed, with lower QoL reported among women, younger individuals, and those with lower socioeconomic status. Conclusions: The COVID-19 pandemic was associated with substantial declines in QoL across population groups, shaped by psychological, social, and structural factors. Findings highlight the importance of addressing social inequalities and enhancing resilience in future public health crises.},
}

@article {pmid41375068,
year = {2025},
author = {Isidoro, C},
title = {SARS-CoV2 and Anti-COVID-19 mRNA Vaccines: Is There a Plausible Mechanistic Link with Cancer?.},
journal = {Cancers},
volume = {17},
number = {23},
pages = {},
doi = {10.3390/cancers17233867},
pmid = {41375068},
issn = {2072-6694},
abstract = {To contrast the COVID-19 pandemic brought by the corona virus SARS-CoV-2, two mRNA-based anti-COVID-19 vaccines (by Pfizer-BioNTech and Moderna) were made available relatively quickly and deployed worldwide based on an emergency approval. Being considered vulnerable and at risk of infection, cancer patients have been prioritized for COVID-19 vaccination and vaccinated repeatedly because of the short time protection provided by these vaccines. Recently, a surge in the incidence and rapid progression of cancers has been observed in many countries, which could (at least partially) represent cancers undiagnosed or untreated during the pandemic. It has also been suggested that the SARS-CoV-2 itself or even the anti-COVID-19 mRNA vaccines could have contributed to the recurrence and worse clinical outcome in cancer patients, given the high incidence of COVID-19 in hospitalized patients and that these patients have been vaccinated with priority several times and in a short period. Although it appears extremely unlikely that SARS-CoV-2 and anti-COVID-19 mRNA vaccines elicit genotoxic events and cause neo-cancerogenesis in a short time, they could still cause non-genotoxic pro-carcinogenic effects by triggering an exaggerated inflammatory reaction, compromising immune homeostasis, stimulating cell proliferation, and negatively affecting cellular stress response and damage repair machinery. This could result in the promotion of regrowth of dormant micrometastases or relapses of stable minimal residual disease. Such a harmful outcome may likely result from a synergy between the virus and the vaccine, especially in multi-vaccinated and multi-infected individuals. Here, I bring the cell pathologist's point of view and discuss the multiple possible mechanisms by which the virus and the anti-COVID-19 mRNA vaccine might favor tumorigenesis. While a causal link cannot be established at this stage, knowledge of potential carcinogenic risks could help doctors and health policymakers take the best actions to protect vulnerable patients and convince the vaccine developer to design a vaccine free from such harm.},
}

@article {pmid41374027,
year = {2025},
author = {Koliou, MP and Skalkos, D},
title = {Post-Pandemic Shifts in Sustainable Food Behavior: A Systematic Review of Emerging Consumer Trends.},
journal = {Nutrients},
volume = {17},
number = {23},
pages = {},
doi = {10.3390/nu17233737},
pmid = {41374027},
issn = {2072-6643},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Feeding Behavior/psychology ; *Consumer Behavior ; *Food Preferences/psychology ; SARS-CoV-2 ; Pandemics ; Hunger ; Female ; Emotions ; Male ; },
abstract = {The COVID-19 pandemic and its associated economic stressors have profoundly reshaped consumer eating behaviors, presenting an urgent and underexplored challenge for the academic community. This interdisciplinary review critically examines how these disruptions have influenced both food approach and food avoidance patterns, offering a structured analysis of eight key behavioral parameters: Hunger (H), Food Responsiveness (FR), Emotional Overeating (EOE), Enjoyment of Food (EF), Satiety Responsiveness (SR), Emotional Under Eating (EUE), Food Fussiness (FF), and Slowness in Eating (SE). Drawing on recent literature, we highlight significant shifts in these traits-such as heightened hedonic hunger, age-related changes in food preferences, and gender-specific emotional-satiety dynamics-underscoring the complex interplay between emotional states, physiological cues, and behavioral tendencies. Grounded in the systematic examination of peer-reviewed studies in the post-COVID period, this review offers a robust and comprehensive synthesis of current evidence. The novelty of this work lies in its integration of findings into targeted proposition statements for each parameter, visually supported by original flow charts. These culminate in the development of a "Consumers' Eating Behavior Index"-a conceptual tool designed to guide researchers, healthcare professionals, and policymakers in understanding and responding to post-pandemic dietary transformations. By emphasizing the emotional and psychological dimensions of eating, this index offers a timely framework for designing tailored public health interventions that promote sustainable nutritional habits. This study calls for renewed academic attention to the behavioral consequences of global crises, positioning eating behavior research as a critical frontier in post-COVID recovery and resilience.},
}

Humans
*COVID-19/psychology/epidemiology
*Feeding Behavior/psychology
*Consumer Behavior
*Food Preferences/psychology
SARS-CoV-2
Pandemics
Hunger
Female
Emotions
Male

@article {pmid41373962,
year = {2025},
author = {Rosanoff, A and von Ehrlich, B and Nelson, D},
title = {A Proposed Scale to Assess Magnesium Status Using Serum Calcium and Magnesium Ratios.},
journal = {Nutrients},
volume = {17},
number = {23},
pages = {},
doi = {10.3390/nu17233671},
pmid = {41373962},
issn = {2072-6643},
mesh = {Humans ; *Magnesium/blood ; *Calcium/blood ; COVID-19/blood/mortality ; Biomarkers/blood ; *Magnesium Deficiency/blood/diagnosis ; SARS-CoV-2 ; Adult ; Female ; Male ; Middle Aged ; },
abstract = {Background/Objectives: Reliable markers of human magnesium (Mg) status are needed. Methods: Current Mg studies report ratios between serum Mg and calcium (Ca) using four interchangeable expressions (i.e., molar or weight calculations of Mg/Ca or Ca/Mg). We propose a scale using ratios of serum Mg and Ca to assess Mg status, unified for all four expressions. We explore its application for case studies and published research. Results:Case Studies (4)-the proposed serum Mg/Ca scale showed better Mg diagnostic value than serum Mg alone. Published Studies-A. The proposed Mg/Ca scale's "depleted Mg" status predicted mortality among hospitalized COVID-19 patients in ROC/AUC analyses. B. The serum Ca/Mg proposed scale, when applied to "healthy" adults with "normal" serum Mg, exposed a "seriously depleted" to "adequate" range of Mg status. C. In a study of periodontal disease, patients designated "adequate" or "mild" Mg depletion by the proposed scale showed greater 5-year improvement than those with scale's "moderate to serious" Mg depletion status. D. Finally, the proposed scale demonstrated appropriate diagnostic value of serum Ca/Mg in acute coronary syndrome patients only when "corrected Ca" was NOT used in ratio calculation. Conclusions: The proposed scale needs both total serum Ca and Mg measures in identical units, i.e., mg/dL or mg% (for weight ratios); mmol/L or mEq/L (for molar ratios). Authors/reviewers/editors need to take care when reporting units/methodology of serum Mg and Ca ratios for clear reporting as to weight or molar ratio and use of total or corrected values. Future trials and statistical testing are needed to determine whether ratios between serum Mg and Ca yield more precise measures of physiological Mg status than serum Mg alone. Our findings indicate the proposed scale is worthy of further study as a marker of Mg deficit.},
}

Humans
*Magnesium/blood
*Calcium/blood
COVID-19/blood/mortality
Biomarkers/blood
*Magnesium Deficiency/blood/diagnosis
SARS-CoV-2
Adult
Female
Male
Middle Aged

@article {pmid41373540,
year = {2025},
author = {Popa, AE and Popa, E and Dramba, T and Coman, EA and Poroch, M and Ungureanu, M and Bacusca, A and Slanina, AM and Bacoanu, G and Poroch, V},
title = {Dysregulated Resolution of Inflammation After Respiratory Viral Infections: Molecular Pathways Linking Neuroinflammation to Post-Viral Neuropathic Pain-A Narrative Review.},
journal = {International journal of molecular sciences},
volume = {26},
number = {23},
pages = {},
doi = {10.3390/ijms262311383},
pmid = {41373540},
issn = {1422-0067},
mesh = {Humans ; *Neuroinflammatory Diseases/immunology/etiology/metabolism/pathology ; *Neuralgia/immunology/etiology/virology ; *COVID-19/complications/immunology ; Animals ; *Inflammation ; SARS-CoV-2 ; Microglia/immunology/metabolism ; Mitochondria/metabolism ; Signal Transduction ; Macrophages/immunology/metabolism ; Immunity, Innate ; *Respiratory Tract Infections/complications/immunology ; },
abstract = {Post-viral neuroinflammatory syndromes, particularly those occurring after SARS-CoV-2 infection, have received increasing attention due to their complex and persistent neurological manifestations. The aim of this narrative review is to integrate current evidence on the molecular and cellular mechanisms underlying chronic neuroinflammation following viral infections, with a focus on dysregulated innate immune responses, macrophage-microglia interactions, oxidative-mitochondrial stress, and impaired inflammation resolution pathways. Our synthesis shows that prolonged activation of macrophages and glial cells promotes the continuous release of pro-inflammatory mediators, while defective phagocytosis and inadequate clearance of cellular debris maintain an inflammatory microenvironment. Mitochondrial dysfunction further amplifies immune activation by stimulating metabolic stress and reactive oxygen species production. In parallel, deficiencies in mediators specialized in inflammation resolution impede the transition from inflammation to resolution, allowing neuroimmune imbalance and nociceptive sensitization to persist long after virus clearance. Key conclusions indicate that these interconnected mechanisms collectively contribute to the long-term neurological symptoms observed in post-viral states, including cognitive impairment, neuropathic pain, and fatigue. Emerging therapeutic strategies targeting cytokine signaling, microglial reactivity, mitochondrial function, and resolution pathways are promising, but remain insufficiently validated in clinical practice. Overall, evidence suggests that post-viral neuroinflammation results from the convergence of sustained immune activation and failure of endogenous resolution mechanisms, highlighting the need for further mechanistic studies and targeted interventions.},
}

Humans
*Neuroinflammatory Diseases/immunology/etiology/metabolism/pathology
*Neuralgia/immunology/etiology/virology
*COVID-19/complications/immunology
Animals
*Inflammation
SARS-CoV-2
Microglia/immunology/metabolism
Mitochondria/metabolism
Signal Transduction
Macrophages/immunology/metabolism
Immunity, Innate
*Respiratory Tract Infections/complications/immunology

@article {pmid41373500,
year = {2025},
author = {Leonardi, R and Lo Bianco, M and Spinello, S and Betta, P and Gagliano, C and Calabrese, V and Polizzi, A and Malaguarnera, G},
title = {Resveratrol as an Adjunct Antiviral Agent in Pediatric Viral Infections: A Review on Mechanistic Insights and Gut Microbiota Modulation.},
journal = {International journal of molecular sciences},
volume = {26},
number = {23},
pages = {},
doi = {10.3390/ijms262311341},
pmid = {41373500},
issn = {1422-0067},
mesh = {Humans ; *Resveratrol/therapeutic use/pharmacology ; *Gastrointestinal Microbiome/drug effects ; *Antiviral Agents/therapeutic use/pharmacology ; Child ; *Virus Diseases/drug therapy/microbiology ; SARS-CoV-2/drug effects ; Dysbiosis/drug therapy ; COVID-19 ; Rotavirus/drug effects ; },
abstract = {Pediatric viral infections impose a heavy burden on child health, often worsened by infection-induced gut dysbiosis. Resveratrol, a natural polyphenol with antiviral, anti-inflammatory, and microbiota-modulating properties, has been proposed to interrupt this pathogenic feedback. To our knowledge, this is the first narrative review focused on resveratrol's antiviral activity in pediatric viral infections, concurrently evaluating its impact on the gut microbiota and their interrelationship. We synthetized preclinical and the limited available pediatric clinical data regarding resveratrol's effect on SARS-CoV-2, respiratory syncytial virus, influenza, rotavirus, and norovirus, extracting information on the models, routes of administration, dosages, mechanisms, and outcomes. Resveratrol interferes with viral lifecycles via diverse mechanisms (modulation of host signaling cascades, capsid or structural protein interactions, and suppression of pro-viral chaperones) while concurrently reshaping the gut microbiota (reducing opportunistic taxa and enriching beneficial genera such as Bifidobacterium and Lactobacillus) leading to improved short-chain fatty acid profiles, barrier integrity, and dampened inflammation. Intranasal resveratrol in children shows clinical benefit, while oral use is underexplored and limited by poor bioavailability; adult data hint at supportive microbiome and anti-inflammatory effects if the delivery is optimized. These dual antiviral and microbiome-directed effects position resveratrol as a promising adjunct in pediatric viral disease management, though well-powered pediatric clinical trials are needed to define dosages, delivery strategies, and the contribution of microbiota-mediated synergy.},
}

Humans
*Resveratrol/therapeutic use/pharmacology
*Gastrointestinal Microbiome/drug effects
*Antiviral Agents/therapeutic use/pharmacology
Child
*Virus Diseases/drug therapy/microbiology
SARS-CoV-2/drug effects
Dysbiosis/drug therapy
COVID-19
Rotavirus/drug effects

@article {pmid41373396,
year = {2025},
author = {Shiel, EV and Connor, Z and Downes, M and Bailey-Shaw, A and Hemingway, S and Walters, C and Kola-Palmer, S},
title = {What Evidence Exists on the Effectiveness of Psychotherapy for Trauma-Related Distress? A Scoping Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233180},
pmid = {41373396},
issn = {2227-9032},
abstract = {Background/Objectives: Trauma-related distress poses significant mental health challenges, with psychotherapy serving as a primary intervention. The Walters Method is a promising new alternative that may help where traditional methods fall short (i.e., in complex or violent cases), but before it can be implemented widely, the existing evidence on the effectiveness of other psychotherapies for trauma-related distress must be mapped to see how and where it relates to other techniques. The aim of this scoping review was to provide an overview of existing evidence on the effectiveness of psychotherapy for trauma-related distress. Methods: A scoping review was conducted to better understand the effectiveness of psychotherapies for trauma-related distress (including PTSD, acute stress disorder, or other serious mental health issues). Results: Thirty-three articles were analysed. Included articles included adults with PTSD, incarcerated women, childbirth trauma survivors, female survivors of sexual abuse, hospitalised COVID-19 patients, adults with serious mental illness, veterans and active soldiers, firefighters, and refugees. Eye Movement Desensitisation and Reprocessing and Cognitive Behavioural Therapy were the most studied and effective treatments. Prolonged Exposure and Narrative Exposure Therapy were less common but noteworthy. Other therapies, including psychodynamic approaches, are seldom studied but have proven effective when explored, highlighting knowledge gaps and potential missed opportunities. Success with these alternative approaches-especially in complex trauma cases like intimate partner violence or child loss where EMDR and CBT may be less effective-suggests they have potential, but further research is needed for validation. Conclusions: This review offers novel contributions to the field by emphasising innovative therapeutic perspectives that extend beyond traditional, more studied, evidence-based approaches such as CBT and EMDR, thereby expanding treatment options for diverse clinical presentations. Alternative therapies show promise, particularly for complex trauma cases like intimate partner violence or child loss where established approaches may be less effective; however, further research is needed to validate their efficacy across diverse populations. Selection of psychotherapy should be based on clients' goals and comfort, and the cultural and contextual compatibility between the person and intervention. Future research should prioritise underexplored therapies to address current knowledge gaps and improve treatment accessibility for varied clinical needs.},
}

@article {pmid41373324,
year = {2025},
author = {Haimi, M and Inchi, L},
title = {Bridging Distance, Delivering Care: Pediatric Tele-Nutrition in the Digital Health Era-A Narrative Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233107},
pmid = {41373324},
issn = {2227-9032},
abstract = {BACKGROUND: The emergence of telehealth has transformed healthcare delivery across multiple disciplines, with tele-nutrition representing a rapidly evolving field that addresses nutritional assessment, counseling, and management through digital platforms.

OBJECTIVE: This narrative review examines the current landscape of pediatric tele-nutrition services, exploring technological platforms, clinical applications, evidence for effectiveness, implementation considerations, and future directions.

METHODS: A comprehensive literature search was conducted across PubMed, CINAHL, Embase, and Web of Science databases from January 2010 to October 2025. A total of 114 relevant sources were selected, encompassing randomized controlled trials, observational studies, systematic reviews, implementation studies, clinical guidelines, and policy documents.

RESULTS: This review synthesized 114 sources, predominantly from the United States (54%) and European nations (21%), with evidence expansion accelerating post-COVID-19 pandemic. Evidence suggests pediatric tele-nutrition demonstrates clinical outcomes comparable to traditional in-person care across diverse populations including obesity management, diabetes, gastrointestinal disorders, feeding difficulties, metabolic conditions, and preventive nutrition services. Multiple technology platforms are utilized, with synchronous video consultations most common (60-85% of encounters). Benefits include enhanced access to specialized care, increased frequency of contact, reduced family burden, and high satisfaction rates (>80% across most studies). Challenges include limitations in physical assessment, digital equity concerns affecting vulnerable populations, variable reimbursement policies, and the need for provider training. Hybrid models combining virtual and in-person care appear optimal for many conditions.

CONCLUSIONS: Pediatric tele-nutrition represents a viable and effective care delivery model with particular advantages for families facing geographic, logistic, or access barriers. Continued attention to digital equity, provider training, regulatory frameworks, sustainable reimbursement policies, and rigorous evidence generation will optimize implementation and outcomes. Future directions include artificial intelligence applications, precision nutrition approaches, and expanded global health applications.},
}

@article {pmid41373248,
year = {2025},
author = {Alagood, J and Senn, WD and Prybutok, G},
title = {Hybrid Analysis of Videoconference Technology Use by Aging-in-Place Organizations to Promote Social Engagement for Older Adults: A Scoping Review with Latent Topic Modeling.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233031},
pmid = {41373248},
issn = {2227-9032},
abstract = {Background/Objectives: Loneliness and social isolation are common among older adults and linked to adverse health outcomes. Videoconferencing can support social connections, but the role of aging-in-place organizations (AIPOs), such as senior centers and Area Agencies on Aging, in facilitating adoption is poorly understood. This review examined how AIPOs use relational videoconferencing to promote social engagement among older adults. Methods: We applied a hybrid methodology combining a scoping review with latent topic modeling to contextualize and analyze the evidence base. Exploratory searches revealed limited literature specifically addressing AIPO involvement; therefore, we first conducted latent topic modeling of the broader literature on social videoconferencing among older adults to establish a thematic foundation for the subsequent PRISMA-guided scoping review. Thematic analysis of this broader corpus, identified through 2021 database searches, applied Latent Dirichlet Allocation (LDA) to a collection of peer-reviewed articles. Subsequent refinement of this corpus by removing non-primary research and non-AIPO records produced the narrower PRISMA subset used for the scoping review. The scoping review followed JBI guidelines and was based on database searches (EBSCOhost: MEDLINE, AgeLine, SocINDEX, Health Source: Nursing/Academic Edition, and Family & Society Studies Worldwide; ProQuest Social Science Premium Collection; and PubMed, including MEDLINE, PMC, and in-process content) for peer-reviewed studies published between 2011 and 2025. Inclusion criteria required primary research involving adults aged 65 years or older, use of videoconferencing technology for social engagement, and reference to AIPOs or analogous community-based aging services. The protocol was post-registered with the Open Science Framework. Results: The LDA analysis of 101 peer-reviewed articles identified six latent themes describing the broader research landscape: problem of isolation, character of socialization, physical health, technology as intervention, technology as social medium, and supportive environments. This thematic framework informed the scoping review, which screened 1908 records and retained 25 publications (representing 24 unique studies) explicitly referencing AIPO involvement in relational videoconferencing. Only one study predated COVID-19. Mapping these studies to the LDA-derived themes revealed the least consistent coverage to be in supportive environments and physical health, particularly among AIPOs other than senior or community centers. Conclusions: Relational videoconferencing has potential to sustain and expand older adults' social connections, but evidence mapped through the scoping review shows that documentation of how AIPOs support adoption is sparse. The hybrid approach advances understanding of videoconferencing in aging contexts and identifies priorities for documenting, comparing, and refining AIPO practices to inform future interventions and policy.},
}

@article {pmid41373238,
year = {2025},
author = {Diener, BL and Berdella, M and DeCelie-Germana, J and Stables-Carney, T and Kier, C},
title = {Transforming Care Models in Cystic Fibrosis: A Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233022},
pmid = {41373238},
issn = {2227-9032},
abstract = {Cystic fibrosis (CF) is a multisystemic, chronic disease that requires a large multidisciplinary team for effective treatment. Over the past 20 years, the landscape of cystic fibrosis care has evolved from an almost exclusively pediatric disease to both a pediatric and adult condition. The median age of cystic fibrosis patients is rising, and the number of adults with CF is also increasing. With new developments in cystic fibrosis care, patients' health and needs have changed, and therefore the care model of the cystic fibrosis team has also changed. The introduction of highly effective CFTR modulator therapy, the COVID-19 pandemic, and the partnership of people with CF (PwCF) and their families have catalyzed the transformation of the CF care model, which includes the growth and evolution of the CF care team given the changes in the demographics of CF patients and the incorporation of telehealth and remote patient monitoring, shared decision-making, and coproduction of care. This narrative review, focusing on the United States (US) experience, explores the transformation of CF care, highlighting demographic changes, medical breakthroughs, and systemic adaptations.},
}

@article {pmid41373226,
year = {2025},
author = {Narymbayeva, N and Kamaliev, M and Juszkiewicz, KT and Kanafyanova, K and Aliyeva, S and Aitambayeva, N and Nazarova, L and Moiynbayeva, S and Saktapov, A and Svetlanova, S},
title = {Temporal and Contextual Variations in Job Satisfaction Between Physicians and Nurses: A Systematic Review and Meta-Analysis.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233008},
pmid = {41373226},
issn = {2227-9032},
abstract = {Objectives: This systematic review and meta-analysis evaluated differences in job satisfaction scores between nurses and physicians, examining variation by (a) care setting (hospital, emergency department, outpatient, mixed), and (b) time period (pre-COVID, during COVID, post-COVID). Methods: We systematically searched PubMed, Scopus, ScienceDirect, Web of Science, and CINAHL for studies published between January 2020 and July 2025. Eligible studies reported mean and standard deviation values for job satisfaction among physicians and nurses in healthcare settings across the specified timeframes. Studies were excluded if they assessed other types of satisfaction or combined data across COVID periods. Pooled standardized mean difference (SMD) was calculated using random-effects models in R. Results: Before COVID-19, the SMD was -2.40 (95% CI -8.05 to 3.26; I[2] = 98%). During the pandemic, the estimate was 1.39 (95% CI -0.57 to 3.35; I[2] = 91.5%), and post-pandemic, it remained small (SMD = 0.29; 95% CI -1.63 to 2.22; I[2] = 95.8%). Emergency care during COVID showed a significant advantage for physicians (SMD = 0.29; 95% CI 0.05 to 0.52; I[2] = 0%). Post-COVID, mixed settings slightly favored physicians (SMD = 0.06), while primary care favored nurses (SMD = -0.30); subgroup differences were significant. Conclusions: The findings reveal that job satisfaction is not solely determined by professional role but is significantly influenced by temporal and contextual factors. Job satisfaction is shaped more by temporal and contextual factors than by professional role. While no consistent differences were observed pre-pandemic, emergency care favored physicians during COVID, and post-pandemic trends showed modest advantages for nurses in primary care and physicians in mixed settings. Due to the methodological limitations of this meta-analysis, including high heterogeneity, reliance on cross-sectional data, and very low/low certainty of evidence, these results should be interpreted with caution.},
}

@article {pmid41369839,
year = {2025},
author = {Obradovic, J and Jurisic, V},
title = {The - 216G/T polymorphism in the EGFR gene: A review focusing on Non-Small lung cancer.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {172},
pmid = {41369839},
issn = {1573-4978},
support = {Agreements No. 451-03-136/2025-03/200378//The Ministry of Science, Technological Development and Innovation, Republic of Serbia/ ; Agreements No. 451-03-137/2025-03/200111//The Ministry of Science, Technological Development and Innovation, Republic of Serbia,/ ; },
mesh = {Humans ; *Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; *Polymorphism, Single Nucleotide/genetics ; *Lung Neoplasms/genetics ; Genetic Predisposition to Disease ; Mutation ; Promoter Regions, Genetic ; },
abstract = {The epidermal growth factor receptor (EGFR) is a key regulator of cell proliferation and a well-established therapeutic target in non-small-cell lung cancer (NSCLC). Somatic mutations in the EGFR gene have been widely studied in the context of tyrosine kinase inhibitors (TKIs), but germline polymorphisms as potentially predictive biomarkers have emerged as a variants of interest over the years. Among these, the - 216G/T (rs712829) single nucleotide polymorphism (SNP), located in the EGFR promoter region, is gaining attention for its potential clinical relevance. This narrative review aims to provide a comprehensive chronological overview of the discovery, functional implications, clinical relevance, and broader oncological and non-oncological associations of the EGFR - 216G/T SNP. Relevant studies were identified from 2005 to 2025 through literature searches across publicly available databases and bibliographies of key publications. This SNP was associated to increased EGFR promotor activity, pleural metastasis, susceptibility to EGFR mutations, NSCLC risk, and different inter-individual and inter-ethnic allele frequencies. Conflicting findings regarding survival outcomes and toxicity underscore the need for further validation. Beyond NSCLC, this SNP has demonstrated relevance in colorectal cancer, glioma, breast cancer, cardiovascular disease, and even COVID-19 susceptibility. The - 216G/T polymorphism represents a promising germline biomarker for NSCLC susceptibility. However, population-specific studies and investigations integrating multi-omics data, along with machine learning models are essential to clarify its utility in precision oncology.},
}

Humans
*Carcinoma, Non-Small-Cell Lung/genetics
ErbB Receptors/genetics
*Polymorphism, Single Nucleotide/genetics
*Lung Neoplasms/genetics
Genetic Predisposition to Disease
Mutation
Promoter Regions, Genetic

@article {pmid40367274,
year = {2025},
author = {Hau, J and Chan, SCC and Hussain, I and Kelly, J and Rashid, MA},
title = {Implementation of virtual pathology teaching in health professions education: A systematic review: BEME Systematic Review No. 95.},
journal = {Medical teacher},
volume = {47},
number = {12},
pages = {1918-1926},
doi = {10.1080/0142159X.2025.2497890},
pmid = {40367274},
issn = {1466-187X},
mesh = {Humans ; *Education, Distance/organization & administration/methods ; COVID-19/epidemiology ; *Pathology/education ; *Health Occupations/education ; SARS-CoV-2 ; Education, Medical ; },
abstract = {PURPOSE: Rapid changes to learning technologies, accelerated by the COVID-19 pandemic, have led to the widespread adoption of virtual education. Pathology is an important medical science that is central to many curricula in health professions education (HPE). It has been impacted by the broader transition to virtual education. This systematic review and meta-ethnography evaluated the experiences of virtual pathology education within HPE.

METHODS: MEDLINE and EMBASE were systematically searched for peer-reviewed qualitative journal articles describing the experiences of virtual pathology in HPE. Of 1119 articles identified, 17 were synthesised using a meta-ethnographic approach.

RESULTS: The final synthesis represented a total of 2126 participants, including 1256 undergraduate medical students, 297 resident doctors, 473 senior clinicians, and 100 teaching faculty. We identified the following third-order constructs: 'Adaptability to learner's needs', 'negative human consequences', and 'uncertainty about trajectory'.

CONCLUSION: This review highlights both positive and negative impacts of transitioning pathology education to virtual delivery. The need to enhance current educational practice according to these findings is particularly pressing since the shift to virtual education in pathology looks set to accelerate in years to come.},
}

Humans
*Education, Distance/organization & administration/methods
COVID-19/epidemiology
*Pathology/education
*Health Occupations/education
SARS-CoV-2
Education, Medical

@article {pmid36922164,
year = {2023},
author = {, and , and , and , },
title = {[Expert consensus on diagnosis and treatment of COVID-19 infection related cough in children].},
journal = {Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]},
volume = {57},
number = {3},
pages = {309-317},
doi = {10.3760/cma.j.cn112150-20230120-00052},
pmid = {36922164},
issn = {0253-9624},
support = {BE2021656//Jiangsu Province Key Research and Development Program (Social Development Project)/ ; SZYJTD201806//Suzhou "Clinical Medicine Expert Team"/ ; 82070009, 82270018//National Nature Science Fundation of China/ ; },
mesh = {Child ; Humans ; *Cough/diagnosis/etiology/therapy ; *COVID-19/therapy ; SARS-CoV-2 ; Consensus ; COVID-19 Testing ; },
abstract = {An epidemic outbreak of the corona virus disease 2019(COVID-19) Omicron variant occurred in most regions of China. Children are susceptible to COVID-19 and the vast majority of them suffer from upper respiratory tract infection. Cough is one of the most common symptoms. COVID-19 infection related cough includes acute cough, persistent cough and chronic cough, and children with original chronic cough or chronic lung disease can also induce or aggravate symptom of cough after infection, which has a great impact on children's physical and mental health. The treatment for COVID-19 infection related cough vary with the etiology. Improper treatment would delay the patient's condition and increase adverse drug reaction. Currently, there is no guideline or consensus on the diagnosis and treatment of COVID-19 infection related cough in children in China, therefore this consensus is drafted. Referring to the latest international research and the diagnostic and therapeutic strategy for COVID-19 infection (Tenth Edition For Trial Implementation), and combining with clinical diagnosis and treatment experience,the consensus elaborates the pathogenesis and etiology of COVID-19 infection related cough, the use of cough relievers and expectorants, as well as the key points of diagnosis and treatment of different etiological factors. It is expected to provide specific and feasible guidance scheme for pediatricians, general practitioners and clinical pharmacists.},
}

Child
Humans
*Cough/diagnosis/etiology/therapy
*COVID-19/therapy
SARS-CoV-2
Consensus
COVID-19 Testing

@article {pmid36822865,
year = {2023},
author = {, and , and , and , },
title = {[Expert consensus on the infection prevention and control of SARS-CoV-2 Omicron variant in healthcare facilities].},
journal = {Zhonghua yi xue za zhi},
volume = {103},
number = {8},
pages = {545-558},
doi = {10.3760/cma.j.cn112137-20220929-02059},
pmid = {36822865},
issn = {0376-2491},
support = {2020-53//China National Health Development Research Center "Evidence Based Evaluation and Demonstration Base Construction Project for Medical Institutions' Sense and Control Measures"/ ; 20411950104//Emergency Science and Technology Project of Science and Technology Commission of Shanghai Municipality/ ; SHDC22021315//Shanghai Hospital Development Center Foundation/ ; 20411950104//Shanghai Committee of Science and Technology/ ; },
mesh = {Humans ; *COVID-19 ; Consensus ; SARS-CoV-2 ; Delivery of Health Care ; },
abstract = {SARS-CoV-2 has been mutating ever since COVID-19 became a global pandemic in 2020, resulting in changes in its viral characteristics. Dealing with infections due to the Omicron variant, it is important for healthcare facilities to dynamically carry out accurate and scientific prevention and control strategies. The current consensus aimed to target the most concerned aspects, including the detection, transmission, prevention and disinfection of the Omicron variant. Through reviewing the latest evidence-based literature, rounds of discussions, and multiple revisions, the panel of experts formed 22 evidence-based recommendations. This consensus provides scientific and practical guidance for the medical institutions, as well as providing reference for other professional organizations and personnel.},
}

Humans
*COVID-19
Consensus
SARS-CoV-2
Delivery of Health Care

@article {pmid36629948,
year = {2023},
author = {Ishige, T and Shimizu, T and Watanabe, K and Arai, K and Kamei, K and Kudo, T and Kunisaki, R and Tokuhara, D and Naganuma, M and Mizuochi, T and Murashima, A and Inoki, Y and Iwata, N and Iwama, I and Koinuma, S and Shimizu, H and Jimbo, K and Takaki, Y and Takahashi, S and Cho, Y and Nambu, R and Nishida, D and Hagiwara, SI and Hikita, N and Fujikawa, H and Hosoi, K and Hosomi, S and Mikami, Y and Miyoshi, J and Yagi, R and Yokoyama, Y and Hisamatsu, T},
title = {Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.},
journal = {Journal of gastroenterology},
volume = {58},
number = {2},
pages = {135-157},
pmid = {36629948},
issn = {1435-5922},
support = {20316729//Ministry of Health, Labour and Welfare/ ; },
mesh = {Adult ; Pregnancy ; Female ; Humans ; Child ; Consensus ; Japan ; *COVID-19 ; *Inflammatory Bowel Diseases/drug therapy ; Vaccination/adverse effects ; },
abstract = {Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients' IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.},
}

Adult
Pregnancy
Female
Humans
Child
Consensus
Japan
*COVID-19
*Inflammatory Bowel Diseases/drug therapy
Vaccination/adverse effects

@article {pmid36599436,
year = {2023},
author = {, and , },
title = {[Expert consensus on treatment of severe COVID-19 caused by Omicron variants].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {46},
number = {2},
pages = {101-110},
doi = {10.3760/cma.j.cn112147-20221230-00994},
pmid = {36599436},
issn = {1001-0939},
support = {2022-NHLHCRF-LX-01-01//National High Level Hospital Clinical Research Funding/ ; 2022-I2M-JB-016//CAMS Innovation Fund for Medical Sciences/ ; 2022YFC2504401//National Key Research and Development Program of China/ ; 2022‑NHLHCRF‑LX‑01‑01//National High Level Hospital Clinical Research Funding/ ; 2022‑I2M‑JB‑016//CAMS Innovation Fund for Medical Sciences/ ; },
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; Consensus ; Critical Care ; China ; },
abstract = {Severe novel coronavirus infection (COVID-19) caused by Omicron variants has arisen in many places of China recently, and critical care is currently the biggest challenge for medical institutions in China. How to manage these patients in a procedural and standardized way to minimize the mortality is a problem that the medical staff with different professional backgrounds has to face. Therefore, the Chinese Thoracic Society and Chinese Association of Chest Physicians Critical Care Group jointly initiated and organized pulmonary and critical care experts to write this recommendation based on the current medical evidence and clinical practice, in order to standardize the clinical treatment of critically ill patients.},
}

Humans
*COVID-19
SARS-CoV-2
Consensus
Critical Care
China

@article {pmid36567574,
year = {2022},
author = {World Federation Of Chinese Medical Societies Emergency Committee, and World Federation Of Chinese Medical Societies Respiratory Diseases, and World Federation Of Chinese Medical Societies Heat Disease Committee, and Chinese Association Of Chinese Medicine Pulmonary Disease Chapter, and The First Aid Group Of Integrated Traditional Chinese And Western Medicine Of The Emergency Branch Of The Chinese Medical Association, and The First Aid Group Of Integrated Traditional Chinese And Western Medicine Of The Emergency Branch Of The Emergency Physician Branch Of The Chinese Medical Doctor Association, and The Emergency Branch Of The Shanghai Chinese Medical Association, and The Institute Of Emergency And Critical Care Of The Shanghai University Of Traditional Chinese Medicine, and National Health Commission's Key Laboratory Of Critical Care Medicine, },
title = {[Expert consensus on traditional Chinese medicine health management in adults with SARS-CoV-2 variant infection at home].},
journal = {Zhonghua wei zhong bing ji jiu yi xue},
volume = {34},
number = {12},
pages = {1233-1237},
doi = {10.3760/cma.j.cn121430-20221210-01079},
pmid = {36567574},
issn = {2095-4352},
mesh = {Adult ; Humans ; SARS-CoV-2 ; *COVID-19 ; Consensus ; East Asian People ; *Drugs, Chinese Herbal/therapeutic use ; China ; Medicine, Chinese Traditional ; },
abstract = {In order to more actively respond to the new situation of prevention and control of coronavirus disease 2019 (COVID-19), and to guide home health management for adults who are asymptomatic carriers or exhibit mild symptoms, the World Federation of Chinese Medical Societies Emergency Committee, World Federation of Chinese Medical Societies Respiratory Diseases, World Federation of Chinese Medical Societies Heat Disease Committee, Chinese Association of Chinese Medicine Pulmonary Disease Chapter, the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Chinese Medical Doctor Association, the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Emergency Physician Branch of the Chinese Medical Association, the Emergency Branch of the Shanghai Chinese Medical Association, the Institute of Emergency and Critical Care of the Shanghai University of Traditional Chinese Medicine, National Health Commission's Key Laboratory of Critical Care Medicine and other academic institutions have organized the medical experts at treating COVID-19 front line in China to investigate and discuss the traditional Chinese medicine (TCM) health management at home for adults infected with SARS-CoV-2 variants, and concluded the "Expert consensus on traditional Chinese medicine health management at home for adults infected with SARS-CoV-2 variants", in combination with "Guideline on SARS-CoV-2 variant infection recover at home" issued by the Joint Prevention and Control Mechanism of the State Council. The expert consensus included home environment, asymptomatic infection, infection with mild symptoms, recovery period, and TCM non-drug therapy intervention, which will provide a guidance to TCM intervention at home to adults infected with SARS-CoV-2 variants.},
}

Adult
Humans
SARS-CoV-2
*COVID-19
Consensus
East Asian People
*Drugs, Chinese Herbal/therapeutic use
China
Medicine, Chinese Traditional

@article {pmid36319453,
year = {2022},
author = {, and , },
title = {[Chinse expert consensus on issues related to the protection, treatment and management of patients with solid tumors during COVID-19 (2022 edition)].},
journal = {Zhonghua zhong liu za zhi [Chinese journal of oncology]},
volume = {44},
number = {10},
pages = {1083-1090},
doi = {10.3760/cma.j.cn112152-20220505-00309},
pmid = {36319453},
issn = {0253-3766},
mesh = {Humans ; *COVID-19 ; Pandemics ; Consensus ; *Neoplasms ; China ; },
abstract = {The new coronavirus is still in the global pandemic stage. At present, the Delta strain and the Omicron strain are the main circulating strains. The mutant strain has stronger infectivity than the original virus. In the content of COVID-19 pandemic, social public resources and medical resources may be affected, which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors. Based on relevant research and clinical practice at home and abroad, the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association, in the light of China's national conditions and the availability of resources such as vaccines and antiviral drug, to formulate a consensus of Chinese experts on issues related to the prevention, treatment and management of patients with solid tumors. The main contents include the vaccination of cancer patients with COVID-19, the optimization of medical resources, and the timing of restarting anti-tumor therapy after COVID-19 infection. This article is aimed at providing reference for clinical practice.},
}

Humans
*COVID-19
Pandemics
Consensus
*Neoplasms
China

@article {pmid36152123,
year = {2022},
author = {Chen, S and Zhao, W and Li, J and Wu, D and , },
title = {Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition).},
journal = {Frontiers of medicine},
volume = {16},
number = {5},
pages = {815-826},
pmid = {36152123},
issn = {2095-0225},
mesh = {Humans ; Consensus ; *Lymphoma, B-Cell/drug therapy ; China ; },
abstract = {Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL) due to their reliable efficacy, manageable safety, high accessibility, and convenience for use. Still, no guidelines or consensus focusing on oral drug therapies for BCL is available. To provide a reference of oral agent-based treatment for mature BCL, a panel of experts from the Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China, combined with the latest authoritative guidelines in the world and current research reports. This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients. With the deepening of research and the development of standardized clinical applications, oral medications will bring better treatment to BCL patients, enabling more patients to benefit from them.},
}

Humans
Consensus
*Lymphoma, B-Cell/drug therapy
China

@article {pmid36103964,
year = {2022},
author = {Shang, Y and Wu, J and Liu, J and Long, Y and Xie, J and Zhang, D and Hu, B and Zong, Y and Liao, X and Shang, X and Ding, R and Kang, K and Liu, J and Pan, A and Xu, Y and Wang, C and Xu, Q and Zhang, X and Zhang, J and Liu, L and Zhang, J and Yang, Y and Yu, K and Guan, X and Chen, D and , },
title = {Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {135},
number = {16},
pages = {1913-1916},
pmid = {36103964},
issn = {2542-5641},
mesh = {Humans ; *COVID-19 ; Consensus ; SARS-CoV-2 ; China ; },
}

Humans
*COVID-19
Consensus
SARS-CoV-2
China

@article {pmid35739055,
year = {2022},
author = {Chen, X and Han, CP and Zhang, W and , },
title = {Shanghai expert consensus on clinical protocol for traditional Chinese medicine treatment of COVID-19 among the elderly population (second edition).},
journal = {Journal of integrative medicine},
volume = {20},
number = {5},
pages = {427-431},
pmid = {35739055},
issn = {2095-4964},
mesh = {Aged ; China ; Clinical Protocols ; Consensus ; Humans ; *Medicine, Chinese Traditional ; SARS-CoV-2 ; *COVID-19 Drug Treatment ; },
abstract = {This document is the revised edition of the previously issued Shanghai Expert Consensus on Clinical Protocol for Traditional Chinese Medicine Treatment of COVID-19 among the Elderly Population. Based on the clinical experience and the Protocol for Diagnosis and Treatment of COVID-19 (Trial 9th Edition), this revised edition provides treatment approaches and recommendations to proactively cope with Omicron variant and increase the therapeutic efficacy for coronavirus disease 2019 among the elderly population in Shanghai, China.},
}

Aged
China
Clinical Protocols
Consensus
Humans
*Medicine, Chinese Traditional
SARS-CoV-2
*COVID-19 Drug Treatment

@article {pmid35381631,
year = {2022},
author = {, },
title = {[Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 version)].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {45},
number = {4},
pages = {341-354},
doi = {10.3760/cma.j.cn112147-20220115-00051},
pmid = {35381631},
issn = {1001-0939},
support = {82161138020, U1801286//National Natural Science Foundation of China/ ; 202102010011//Science and Technology Program of Guangzhou/ ; ZNSA-2020013, ZNSA-2020003//Zhongnanshan Medical Foundation of Guangdong Province/ ; },
mesh = {*Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; *Asthma/drug therapy ; *COVID-19 ; Consensus ; Humans ; Omalizumab/therapeutic use ; Quality of Life ; },
abstract = {As the first targeted biotherapy for asthma, Omalizumab, was officially approved in China in August 2017, and was applied in clinical practice since March, 2018. Dozens of experts in Respirology and Allergy from China fully discussed the important clinical issues on the use of Omalizumab in allergic asthma by referring to the relevant publications over the world and the first version of consensus published in March 2018. Until now, over 30, 000 allergic asthma patients have received the treatment of Omalizumab. Therefore, with the latest evidence of clinical and basic research around the world, we updated the consensus with the following issues: (1) The mechanisms and available evidence on anti-IgE treatment; (2) Selection and exclusion criteria for patients using Omalizumab; (3) Cautions on the administration of Omalizumab and highlights of the use of Omalizumab with various vaccines, including novel Coronavirus vaccines, and key points to note during a Novel Coronavirus pandemic; (4) Long-term use and safety; (5) The use of Omalizumab in specific populations; (6) Clinical applications of omalizumab with other targeted therapies and allergen-specific immunotherapy. Omalizumab, combining to the Cε3 area of IgE, reduces the free IgE level, and downregulates the expression of FcεRⅠ, which inhibits the release of inflammatory mediators of mast cell sources, and leads to reduced asthma exacerbation, decreased rate of emergency visit and hospitalization, improved symptoms and quality of life, as well as less concomitant moderate to severe asthma, poorly controlled after at least 3 months treatment of ICS/LABA, and confirmed with allergic status through skin prick test or serum total IgE or specific IgE. Conditions that exclude the use of Omalizumab include patients who are suspected to be allergic to drug ingredients. Omalizumab is administered based on dosing tables by subcutaneous injection. Omalizumab should be administered by a health care professional (doctor or nurse) in a medical institution equipped with facilities for post-injection observation and rescue treatment for anaphylactic shock. After the injection, the patient should be closely monitored whether there is an anaphylactic reaction. The duration of Omalizumab treatment should be at least 16 weeks to judge its effectiveness, after 16 weeks, Omalizumab treatment will be continued or withdrawn based on the overall asthma control evaluation. Patients should be followed every 3 months to assess the disease control and dosing adjustment. The common adverse reactions were injection sites reactions. Based on the latest evidence around the word, we focused on updating the relevant treatment course, administration method and use of specific populations, in order to guide clinicians in the use of Omalizumab. The use of Omalizumab in China still requires long-term observation and further research. With the increase of clinical evidence, this consensus will be continuously improved and supplemented.},
}

*Anti-Asthmatic Agents/therapeutic use
Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
*Asthma/drug therapy
*COVID-19
Consensus
Humans
Omalizumab/therapeutic use
Quality of Life

@article {pmid35257524,
year = {2022},
author = {Choi, JH and Moon, J and Kim, S and Bae, H and Lee, J and Choe, YJ},
title = {Expert Consensus on COVID-19 Vaccination in Korean Adolescents: A Modified Delphi Survey.},
journal = {Journal of Korean medical science},
volume = {37},
number = {9},
pages = {e69},
pmid = {35257524},
issn = {1598-6357},
support = {2021-10-023//Korea Disease Control and Prevention Agency/Korea ; },
mesh = {Adolescent ; Adult ; *COVID-19/prevention & control ; *COVID-19 Vaccines ; Child ; Consensus ; Humans ; Republic of Korea ; Vaccination ; },
abstract = {The effectiveness of coronavirus disease 2019 (COVID-19) vaccines had been shown in many studies in adult population, however, the real-world evidence in the childhood population was scarce. We aimed to organize the collective expert's opinions on adolescent vaccination against COVID-19 in Korea, therefore to guide the vaccination policy in the setting of available evidence. The Delphi panels responded that adolescents were greatly impacted by the quarantine measures, and COVID-19 is an important health problem for adolescents. Panels responded that in general, the benefits of the COVID-19 vaccine overweigh the potential risks in Korean adolescents. Continuing monitoring of available data is needed to provide the best vaccination practices in adolescents guided by the updated evidence.},
}

Adolescent
Adult
*COVID-19/prevention & control
*COVID-19 Vaccines
Child
Consensus
Humans
Republic of Korea
Vaccination

@article {pmid35125460,
year = {2022},
author = {Iyer, S and Bovonratwet, P and Samartzis, D and Schoenfeld, AJ and An, HS and Awwad, W and Blumenthal, SL and Cheung, JPY and Derman, PB and El-Sharkawi, M and Freedman, BA and Hartl, R and Kang, JD and Kim, HJ and Louie, PK and Ludwig, SC and Neva, MH and Pham, MH and Phillips, FM and Qureshi, SA and Radcliff, KE and Riew, KD and Sandhu, HS and Sciubba, DM and Sethi, RK and Valacco, M and Zaidi, HA and Zygourakis, CC and Makhni, MC},
title = {Appropriate Telemedicine Utilization in Spine Surgery: Results From a Delphi Study.},
journal = {Spine},
volume = {47},
number = {8},
pages = {583-590},
doi = {10.1097/BRS.0000000000004339},
pmid = {35125460},
issn = {1528-1159},
mesh = {*COVID-19/epidemiology ; Consensus ; Delphi Technique ; Humans ; Patient Satisfaction ; *Telemedicine ; },
abstract = {STUDY DESIGN: Delphi expert panel consensus.

OBJECTIVE: To obtain expert consensus on best practices for appropriate telemedicine utilization in spine surgery.

SUMMARY OF BACKGROUND DATA: Several studies have shown high patient satisfaction associated with telemedicine during the COVID-19 peak pandemic period as well as after easing of restrictions. As this technology will most likely continue to be employed, there is a need to define appropriate utilization.

METHODS: An expert panel consisting of 27 spine surgeons from various countries was assembled in February 2021. A two-round consensus-based Delphi method was used to generate consensus statements on various aspects of telemedicine (separated as video visits or audio visits) including themes, such as patient location and impact of patient diagnosis, on assessment of new patients. Topics with ≥75% agreement were categorized as having achieved a consensus.

RESULTS: The expert panel reviewed a total of 59 statements. Of these, 32 achieved consensus. The panel had consensus that video visits could be utilized regardless of patient location and that video visits are appropriate for evaluating as well as indicating for surgery multiple common spine pathologies, such as lumbar stenosis, lumbar radiculopathy, and cervical radiculopathy. Finally, the panel had consensus that video visits could be appropriate for a variety of visit types including early, midterm, longer term postoperative follow-up, follow-up for imaging review, and follow-up after an intervention (i.e., physical therapy, injection).

CONCLUSION: Although telemedicine was initially introduced out of necessity, this technology most likely will remain due to evidence of high patient satisfaction and significant cost savings. This study was able to provide a framework for appropriate telemedicine utilization in spine surgery from a panel of experts. However, several questions remain for future research, such as whether or not an in-person consultation is necessary prior to surgery and which physical exam maneuvers are appropriate for telemedicine.Level of Evidence: 4.},
}

*COVID-19/epidemiology
Consensus
Delphi Technique
Humans
Patient Satisfaction
*Telemedicine

@article {pmid35057603,
year = {2022},
author = {Chopra, HK and Nair, T and Ponde, CK and Kaul, S and Mehta, Y and Vora, A and Mukhopadhyay, P and Jayagopal, PB and Behera, M and Patil, R and Deshpande, M and Anantharaman, R},
title = {COVID-Inflicted Coagulopathy: Expert Consensus on Management with Novel Oral Anticoagulants in India.},
journal = {The Journal of the Association of Physicians of India},
volume = {69},
number = {12},
pages = {11-12},
pmid = {35057603},
issn = {0004-5772},
mesh = {Administration, Oral ; Anticoagulants/therapeutic use ; *COVID-19 ; Consensus ; *Heparin, Low-Molecular-Weight ; Humans ; India/epidemiology ; Pandemics ; SARS-CoV-2 ; },
abstract = {Coronavirus disease 2019 (COVID-19) is a highly hypercoagulable viral infection complicated as COVID-inflicted coagulopathy (CIC), that is associated with increased risk of morbidity and mortality. International guidelines recommend low molecular weight heparin (LMWH) to treat CIC in both in-hospital and in-home settings. However, in India, using subcutaneous LMWH may not be a feasible option for a vast majority of patients under home management. Additionally, while some evidence advocates the use of novel oral anticoagulants (NOACs), in hospitalized settings, most guidelines find no role of NOACs in hospital settings. On the other hand, the resource crunch faced in recent COVID-19 pandemic in India forced physicians to treat many patients in home settings. These patients had been usually prescribed NOACs for ease of administration and adherence. Therefore, there is a need to form a consensus on the use of NOACs to manage CIC in India.},
}

Administration, Oral
Anticoagulants/therapeutic use
*COVID-19
Consensus
*Heparin, Low-Molecular-Weight
Humans
India/epidemiology
Pandemics
SARS-CoV-2

@article {pmid34815248,
year = {2024},
author = {Dewhurst, F and Hanratty, B and Frew, K and Paes, P and Walker, R and Barnes, C and Maddock, H and Elverson, J and Byrne-Davis, L},
title = {Palliative medicine trainees be should learn about frailty: meta-synthesis and Delphi study to establish curriculum content.},
journal = {BMJ supportive & palliative care},
volume = {13},
number = {e3},
pages = {e1008-e1018},
doi = {10.1136/bmjspcare-2021-003013},
pmid = {34815248},
issn = {2045-4368},
mesh = {Aged ; Humans ; Curriculum ; Delphi Technique ; *Frailty/therapy ; Palliative Care ; *Palliative Medicine ; },
abstract = {OBJECTIVES: Frailty is common and highly associated with morbidity and mortality, a fact that has been highlighted by COVID-19. Understanding how to provide palliative care for frail individuals is an international priority, despite receiving limited mention in Palliative Medicine curricula or examinations worldwide. This study aimed to synthesise evidence and establish expert consensus on what should be included in a Palliative-Medicine Specialist Training Curriculum for frailty.

METHODS: Literature Meta-synthesis conducted by palliative medicine, frailty and education experts produced a draft curriculum with Bologna based Learning-Outcomes. A Delphi study asked experts to rate the importance of Learning-Outcomes for specialist-training completion and propose additional Learning-Outcomes. This process was repeated until 70% consensus was achieved for over 90% of Learning-Outcomes. Experts divided Learning-Outcomes into specific (for inclusion in a frailty subsection) or generic (applicable to other palliative conditions). The Delphi panel was Subject Matter Experts: Palliative-Medicine Consultants (n=14) and Trainees (n=10), representing hospital, community, hospice and care home services and including committee members of key national training organisations. A final reviewing panel of Geriatric Medicine Specialists including experts in research methodology, national training requirements and frailty were selected.

RESULTS: The meta-synthesis produced 114 Learning-Outcomes. The Delphi Study and Review by Geriatric Medicine experts resulted in 46 essential and 33 desirable Learning-Outcomes.

CONCLUSIONS: This frailty curriculum is applicable internationally and highlights the complex and unique palliative needs of frail patients. Future research is required to inform implementation, educational delivery and service provision.},
}

Aged
Humans
Curriculum
Delphi Technique
*Frailty/therapy
Palliative Care
*Palliative Medicine

@article {pmid33946120,
year = {2021},
author = {Elalamy, I and Gerotziafas, G and Alamowitch, S and Laroche, JP and Van Dreden, P and Ageno, W and Beyer-Westendorf, J and Cohen, AT and Jimenez, D and Brenner, B and Middeldorp, S and Cacoub, P and , },
title = {SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia.},
journal = {Thrombosis and haemostasis},
volume = {121},
number = {8},
pages = {982-991},
pmid = {33946120},
issn = {2567-689X},
mesh = {COVID-19/*prevention & control ; COVID-19 Vaccines/*adverse effects/therapeutic use ; Clinical Decision-Making ; Hemorrhage/etiology ; Humans ; Purpura, Thrombocytopenic, Idiopathic/*etiology ; Risk Factors ; Thrombocytopenia/etiology ; Thrombosis/*etiology ; Vaccination/adverse effects/methods ; },
abstract = {Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.},
}

COVID-19/*prevention & control
COVID-19 Vaccines/*adverse effects/therapeutic use
Clinical Decision-Making
Hemorrhage/etiology
Humans
Purpura, Thrombocytopenic, Idiopathic/*etiology
Risk Factors
Thrombocytopenia/etiology
Thrombosis/*etiology
Vaccination/adverse effects/methods

@article {pmid33857654,
year = {2021},
author = {Ng, YS and Ong, PH and Mah, SM and Koh, CWC and Loh, YJ and Chew, E},
title = {Rehabilitation prioritization: Development of expert consensus on essential rehabilitation during pandemics.},
journal = {Annals of physical and rehabilitation medicine},
volume = {64},
number = {6},
pages = {101512},
pmid = {33857654},
issn = {1877-0665},
mesh = {Consensus ; Humans ; *Pandemics ; },
}

Consensus
Humans
*Pandemics

@article {pmid33630471,
year = {2021},
author = {Asbun, HJ and Abu Hilal, M and Kunzler, F and Asbun, D and Bonjer, J and Conlon, K and Demartines, N and Feldman, LS and Morales-Conde, S and Pietrabissa, A and Pryor, AD and Schlachta, CM and Sylla, P and Targarona, EM and Agra, Y and Besselink, MG and Callery, M and Cleary, SP and De La Cruz, L and Eckert, P and Evans, C and Han, HS and Jones, DB and Gan, TJ and Koch, D and Lillemoe, KD and Lomanto, D and Marks, J and Matthews, B and Mellinger, J and Melvin, WS and Moreno-Paquentin, E and Navarrete, C and Pawlik, TM and Pessaux, P and Ricciardi, W and Schwaitzberg, S and Shah, P and Szokol, J and Talamini, M and Torres, R and Triboldi, A and Udomsawaengsup, S and Valsecchi, F and Vauthey, JN and Wallace, M and Wexner, SD and Zinner, M and Francis, N},
title = {International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic Practice: From the Coronavirus Global Surgical Collaborative.},
journal = {Annals of surgery},
volume = {274},
number = {1},
pages = {50-56},
pmid = {33630471},
issn = {1528-1140},
mesh = {COVID-19/epidemiology/*prevention & control/transmission ; Consensus ; Delphi Technique ; *Elective Surgical Procedures ; *Endoscopy ; Humans ; Infection Control/*organization & administration ; Internationality ; Intersectoral Collaboration ; Triage ; },
abstract = {OBJECTIVE: The aim of this work is to formulate recommendations based on global expert consensus to guide the surgical community on the safe resumption of surgical and endoscopic activities.

BACKGROUND: The COVID-19 pandemic has caused marked disruptions in the delivery of surgical care worldwide. A thoughtful, structured approach to resuming surgical services is necessary as the impact of COVID-19 becomes better controlled. The Coronavirus Global Surgical Collaborative sought to formulate, through rigorous scientific methodology, consensus-based recommendations in collaboration with a multidisciplinary group of international experts and policymakers.

METHODS: Recommendations were developed following a Delphi process. Domain topics were formulated and subsequently subdivided into questions pertinent to different aspects of surgical care in the COVID-19 crisis. Forty-four experts from 15 countries across 4 continents drafted statements based on the specific questions. Anonymous Delphi voting on the statements was performed in 2 rounds, as well as in a telepresence meeting.

RESULTS: One hundred statements were formulated across 10 domains. The statements addressed terminology, impact on procedural services, patient/staff safety, managing a backlog of surgeries, methods to restart and sustain surgical services, education, and research. Eighty-three of the statements were approved during the first round of Delphi voting, and 11 during the second round. A final telepresence meeting and discussion yielded acceptance of 5 other statements.

CONCLUSIONS: The Delphi process resulted in 99 recommendations. These consensus statements provide expert guidance, based on scientific methodology, for the safe resumption of surgical activities during the COVID-19 pandemic.},
}

COVID-19/epidemiology/*prevention & control/transmission
Consensus
Delphi Technique
*Elective Surgical Procedures
*Endoscopy
Humans
Infection Control/*organization & administration
Internationality
Intersectoral Collaboration
Triage

@article {pmid33484264,
year = {2021},
author = {Ma, B and Fan, X and Kong, W and Xiao, S and Zhu, S and Yao, M and Liu, Y and Zhu, W and Wang, J and Zeng, Y and Zhao, Y and Su, B and Xu, S and Dong, Z and Gu, H and Li, W and Jiang, Y and Gu, D and Xia, Z},
title = {Expert Consensus on Clinical Practice of Burn Units in Shanghai During the COVID-19 Epidemic.},
journal = {Journal of burn care & research : official publication of the American Burn Association},
volume = {42},
number = {4},
pages = {642-645},
doi = {10.1093/jbcr/irab010},
pmid = {33484264},
issn = {1559-0488},
support = {81930057//National Natural Science Foundation of China/ ; 2019-I2M-5-076//CAMS Innovation Fund for Medical Sciences/ ; },
mesh = {Burn Units/*organization & administration ; Burns/epidemiology/*therapy ; COVID-19/*epidemiology/therapy ; China/epidemiology ; *Consensus ; Critical Care/*organization & administration ; Humans ; Infection Control/organization & administration ; },
abstract = {In response to coronavirus disease 2019 (COVID-19), the Shanghai Burn Clinical Quality Control Center organized experts to formulate and implement a set of rapid, simple, and effective prevention and control measures, and there have not been any cases of health care professionals or inpatients in burn units suspected or confirmed with COVID-19. This article elaborates on the specific measures in burn units in response to the epidemic, including the implementation of standardized procedures, remote consultations, strengthened follow-up, exchange of experience, and popular science, among others. We share experience from Shanghai to benefit related disciplines in other countries and regions.},
}

Burn Units/*organization & administration
Burns/epidemiology/*therapy
COVID-19/*epidemiology/therapy
China/epidemiology
*Consensus
Critical Care/*organization & administration
Humans
Infection Control/organization & administration

@article {pmid33394078,
year = {2021},
author = {Lan, X and Long, Y and Shao, F and Song, Y},
title = {Expert consensus on the safety prevention and control of nuclear medicine diagnosis and treatment during the outbreak of COVID-19 (1st edition): (translated from Chinese version).},
journal = {European journal of nuclear medicine and molecular imaging},
volume = {48},
number = {4},
pages = {1134-1143},
pmid = {33394078},
issn = {1619-7089},
mesh = {COVID-19/*prevention & control ; China/epidemiology ; Consensus ; Disease Outbreaks/*prevention & control ; Humans ; Nuclear Medicine/*trends ; SARS-CoV-2 ; },
abstract = {In December 2019, an infectious disease caused by a new type of coronavirus infection was prevalent in Wuhan and across the country. On January 20, 2020, the National Health Commission of the People's Republic of China issued No.1 Announcement, which incorporated the novel coronavirus pneumonia into the Class B infectious disease according to the Law on Prevention and Control of Infectious Disease, but the disease should be adopted in the management of Class A infectious disease. In order to effectively control the source of infection, cut off the transmission route, protect the susceptible population, ensure the medical quality and medical safety, perform epidemic prevention and control, and comprehensively guarantee the life safety and physical health of medical staff, patients, and family members, it is very important to organize and carry out nuclear medicine diagnosis and treatment scientifically and safely. According to the national prevention and control policy, Chinese Society of Nuclear Medicine and editorial board of the Chinese Journal of Nuclear Medicine and Molecular Imaging organized professionals to formulate the expert consensus on the safety prevention process of nuclear medicine imaging and nuclide therapy during the period of new coronavirus infection.},
}

COVID-19/*prevention & control
China/epidemiology
Consensus
Disease Outbreaks/*prevention & control
Humans
Nuclear Medicine/*trends
SARS-CoV-2

@article {pmid33323819,
year = {2020},
author = {Sun, TW and Zhang, XJ and Yu, Z and Shang, Y},
title = {Chinese expert consensus on the diagnosis and treatment of severely and critically ill patients with coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {24},
pages = {2963-2965},
pmid = {33323819},
issn = {2542-5641},
mesh = {COVID-19/diagnosis/*therapy ; Consensus ; Critical Illness ; Humans ; *SARS-CoV-2 ; },
}

COVID-19/diagnosis/*therapy
Consensus
Critical Illness
Humans
*SARS-CoV-2

@article {pmid33272328,
year = {2020},
author = {Chan, Y and Banglawala, SM and Chin, CJ and Côté, DWJ and Dalgorf, D and de Almeida, JR and Desrosiers, M and Gall, RM and Gevorgyan, A and Hassan Hassan, A and Janjua, A and Lee, JM and Leung, RM and Mechor, BD and Mertz, D and Monteiro, E and Nayan, S and Rotenberg, B and Scott, J and Smith, KA and Sommer, DD and Sowerby, L and Tewfik, MA and Thamboo, A and Vescan, A and Witterick, IJ},
title = {CSO (Canadian Society of Otolaryngology - Head & Neck Surgery) position paper on rhinologic and skull base surgery during the COVID-19 pandemic.},
journal = {Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale},
volume = {49},
number = {1},
pages = {81},
pmid = {33272328},
issn = {1916-0216},
mesh = {*COVID-19/diagnosis/epidemiology/prevention & control ; *COVID-19 Testing ; Disease Transmission, Infectious/prevention & control ; Humans ; Nose/*surgery ; Otolaryngology/methods/*standards ; Otorhinolaryngologic Diseases/surgery ; Otorhinolaryngologic Surgical Procedures/*standards ; *Pandemics ; Personal Protective Equipment/*standards ; Postoperative Care/standards ; Preoperative Care/methods/*standards ; Skull Base/*surgery ; },
abstract = {Healthcare services in many countries have been partially or completely disrupted by the Coronavirus (COVID-19) pandemic since its onset in the end of 2019. Amongst the most impacted are the elective medical and surgical services in order to conserve resources to care for COVID-19 patients. As the number of infected patients decrease across Canada, elective surgeries are being restarted in a staged manner. Since Otolaryngologists - Head & Neck Surgeons manage surgical diseases of the upper aerodigestive tract where the highest viral load reside, it is imperative that these surgeries resume in a safe manner. The aim of this document is to compile the current best evidence available and provide expert consensus on the safe restart of rhinologic and skull base surgeries while discussing the pre-operative, intra-operative, and post-operative care and tips. Risk assessment, patient selection, case triage, and pre-operative COVID-19 testing will be analyzed and discussed. These guidelines will also consider the optimal use of personal protective equipment for specific cases, general and specific operative room precautions, and practical tips of intra-operative maneuvers to optimize patient and provider safety. Given that the literature surrounding COVID-19 is rapidly evolving, these recommendations will serve to start our specialty back into elective rhinologic surgeries over the next months and they may change as we learn more about this disease.},
}

*COVID-19/diagnosis/epidemiology/prevention & control
*COVID-19 Testing
Disease Transmission, Infectious/prevention & control
Humans
Nose/*surgery
Otolaryngology/methods/*standards
Otorhinolaryngologic Diseases/surgery
Otorhinolaryngologic Surgical Procedures/*standards
*Pandemics
Personal Protective Equipment/*standards
Postoperative Care/standards
Preoperative Care/methods/*standards
Skull Base/*surgery

@article {pmid33213540,
year = {2021},
author = {Khan, S and Tsang, KK and Mertz, D and Dolovich, M and Tunks, M and Demers, C and Hassall, K and Maharaj, N and Margallo, K and Cividino, M and Chagla, Z and Duong, M},
title = {A regional Canadian expert consensus on recommendations for restoring exercise and pulmonary function testing in low and moderate-to-high community prevalence coronavirus disease 2019 (COVID-19) settings.},
journal = {Infection control and hospital epidemiology},
volume = {42},
number = {12},
pages = {1535-1537},
pmid = {33213540},
issn = {1559-6834},
mesh = {*COVID-19 ; Canada/epidemiology ; Consensus ; Humans ; Prevalence ; SARS-CoV-2 ; },
}

*COVID-19
Canada/epidemiology
Consensus
Humans
Prevalence
SARS-CoV-2

@article {pmid33089297,
year = {2020},
author = {Zhu, L and Wang, JB and Yu, Q and Huang, ZW and Han, FK and Li, SJ and Sha, Y and Shi, HM and Tao, XF},
title = {[Shanghai municipal expert consensus on standardized prevention and control of COVID-19 during procedures of oral radiology].},
journal = {Shanghai kou qiang yi xue = Shanghai journal of stomatology},
volume = {29},
number = {4},
pages = {431-434},
pmid = {33089297},
issn = {1006-7248},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; *Coronavirus Infections ; Humans ; *Pandemics ; *Pneumonia, Viral ; *Radiography, Dental ; SARS-CoV-2 ; },
abstract = {The announcement of National Health Commission on January 20, 2020 (No.1 of 2020) has included novel coronavirus pneumonia into the B class infectious diseases according to the law of the People's Republic of China on the prevention and control of infectious diseases, and has been managed as A class infectious diseases. People's governments at all levels and health administration departments have been paying high attention to it. With the alleviation of COVID-19 nationwide, dental clinics gradually resume to work. The main transmission routes of COVID-19 are respiratory droplets and contact transmission, hence oral radiological examination is kind of a high-risk operation. Standardized radiologic process is of great significance to reduce the risk of COVID-19 transmission. In accordance with the national and Shanghai epidemic prevention requirements, and in combination with the actual situation of various medical institutions, Oral and Maxillofacial Radiology Committee of Shanghai Stomatological Association formulated the expert consensus on standardized prevention and control of COVID-19 for clinical reference. This recommendation will be updated according to the situation of epidemic prevention and control in China and the new relevant diagnosis and treatment plans.},
}

Betacoronavirus
COVID-19
China
Consensus
*Coronavirus Infections
Humans
*Pandemics
*Pneumonia, Viral
*Radiography, Dental
SARS-CoV-2

@article {pmid32852385,
year = {2020},
author = {Yang, XH and Hu, B and Shang, Y and Liu, J and Zhong, M and Shang, XL and Wu, ZX and Yu, Z and Sun, RH and Wang, HL and Zhao, MY and Meng, M and Xu, QH and Zheng, X and Chen, DC},
title = {Expert consensus on management of analgesia and sedation for patients with severe coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {18},
pages = {2186-2188},
doi = {10.1097/CM9.0000000000001034},
pmid = {32852385},
issn = {2542-5641},
mesh = {Analgesia/*methods ; *Betacoronavirus ; COVID-19 ; Conscious Sedation/*methods ; Consensus ; Coronavirus Infections/*complications ; Humans ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; },
}

Analgesia/*methods
*Betacoronavirus
COVID-19
Conscious Sedation/*methods
Consensus
Coronavirus Infections/*complications
Humans
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2

@article {pmid32794674,
year = {2020},
author = {Bone Circulation And Osteonecrosis Professional Committee Shockwave Medical Specialty Committee Of Chinese Research Hospital Association, },
title = {[Expert consensus on prevention and treatment strategies for osteonecrosis of femoral head during the prevention and control of novel coronavirus pneumonia (2020)].},
journal = {Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery},
volume = {34},
number = {8},
pages = {1031-1035},
pmid = {32794674},
issn = {1002-1892},
mesh = {Betacoronavirus ; COVID-19 ; Consensus ; Coronavirus Infections/*epidemiology ; Femur Head/pathology ; Femur Head Necrosis/*prevention & control/*therapy ; Humans ; Osteonecrosis/*prevention & control/*therapy ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; },
abstract = {Novel coronavirus pneumonia is a new type of respiratory infectious disease that has rapidly spread in many countries or regions around the world. The World Health Organization (WHO) named it "coronavirus disease 2019 (COVID-19)". Glucocorticoids (GC) have certain application value in patients with COVID-19, but they need to be used with caution and strict indications and dosage. Application of large doses of GC can also cause osteonecrosis of femoral head (ONFH). On the basis of the latest literature and evidence-based medical evidence on the fight against COVID-19 epidemic and steroid ONFH diagnosis and treatment, the Bone Circulation and Osteonecrosis Professional Committee, Shockwave Medical Specialty Committee of Chinese Research Hospital Association organized Chinese bone necrosis related experts to jointly write this consensus, focusing on the prevention strategy and the protective management measures in the ONFH diagnosis and treatment process during the prevention and control of COVID-19, which can provide reference for hospitals at all levels to carry out early prevention and treatment of ONFH.},
}

Betacoronavirus
COVID-19
Consensus
Coronavirus Infections/*epidemiology
Femur Head/pathology
Femur Head Necrosis/*prevention & control/*therapy
Humans
Osteonecrosis/*prevention & control/*therapy
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2

@article {pmid32641446,
year = {2020},
author = {Wang, F and Liu, J and Zhang, P and Jiang, W and Zhang, L and Zhang, M and Teng, J and Wang, J and Xie, X and Cao, J and Li, W and Wu, Y and Zhou, H and Su, Y and Pan, S and Liu, L},
title = {Expert consensus on prevention and control of COVID-19 in the neurological intensive care unit (first edition).},
journal = {Stroke and vascular neurology},
volume = {5},
number = {3},
pages = {242-249},
pmid = {32641446},
issn = {2059-8696},
mesh = {Betacoronavirus/*pathogenicity ; COVID-19 ; Consensus ; Coronavirus Infections/diagnosis/*prevention & control/transmission/virology ; Critical Illness ; Cross Infection/diagnosis/*prevention & control/transmission/virology ; Host-Pathogen Interactions ; Humans ; Infection Control/*standards ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Intensive Care Units/*standards ; Nervous System Diseases/diagnosis/*therapy ; Neurology/*standards ; Occupational Health ; Pandemics/*prevention & control ; Patient Safety ; Pneumonia, Viral/diagnosis/*prevention & control/transmission/virology ; Risk Assessment ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome ; },
abstract = {During the COVID-19 epidemic, the treatment of critically ill patients has been increasingly difficult and challenging. During the epidemic, some patients with neurological diseases also have COVID-19, which could be misdiagnosed and cause silent transmission and nosocomial infection. Such risk is high in a neurological intensive care unit (NCU). Therefore, prevention and control of epidemic in critically ill patients is of utmost importance. The principle of NCU care should include comprehensive screening and risk assessment, weighing risk against benefits and reducing the risk of COVID-19 transmission while treating patients as promptly as possible.},
}

Betacoronavirus/*pathogenicity
COVID-19
Consensus
Coronavirus Infections/diagnosis/*prevention & control/transmission/virology
Critical Illness
Cross Infection/diagnosis/*prevention & control/transmission/virology
Host-Pathogen Interactions
Humans
Infection Control/*standards
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Intensive Care Units/*standards
Nervous System Diseases/diagnosis/*therapy
Neurology/*standards
Occupational Health
Pandemics/*prevention & control
Patient Safety
Pneumonia, Viral/diagnosis/*prevention & control/transmission/virology
Risk Assessment
Risk Factors
SARS-CoV-2
Treatment Outcome

@article {pmid32627963,
year = {2020},
author = {Corona-Cruz, J and Alba, EG and Iñiguez-García, M and López-Saucedo, R and Olivares-Torres, C and Rodriguez-Cid, J and Salazar-Otaola, G and Martínez-Said, H and Flores, RM and Arrieta, O},
title = {Surgical care of thoracic malignancies during the COVID-19 pandemic in México: An expert consensus guideline from the Sociedad Mexicana de Oncología (SMeO) and the Sociedad Mexicana de Cirujanos Torácicos Generales (SMCTG).},
journal = {Thoracic cancer},
volume = {11},
number = {8},
pages = {2370-2375},
pmid = {32627963},
issn = {1759-7714},
mesh = {COVID-19/complications/*epidemiology/virology ; Guidelines as Topic ; Humans ; Lung Neoplasms/complications/*epidemiology/surgery/virology ; Medical Oncology/trends ; Mexico/epidemiology ; *Pandemics ; SARS-CoV-2/pathogenicity ; Thoracic Neoplasms/complications/*epidemiology/surgery/virology ; Triage ; },
abstract = {To date, the impact, timeline and duration of COVID-19 pandemic remains unknown and more than ever it is necessary to provide safe pathways for cancer patients. Multiple triage systems for nonemergent surgical procedures have been published, but potentially curative cancer procedures are essential surgery rather than elective surgery. In the present and future scenario of our country, thoracic oncology teams may have the difficult decision of weighing the utility of surgical intervention against the risk for inadvertent COVID-19 exposure for patients and medical staff. In consequence, traditional pathways of surgical care must be adjusted to reduce the risk of infection and the use of resources. It is recommended that all thoracic cancer patients should be offered treatment according to the accepted standard of care until shortage of services require a progressive reduction in surgical cases. Here, we present a consensus of recommendations discussed by a multidisciplinary panel of experts on thoracic oncology and based on the best available evidence, and hope it will provide a modifiable framework of guidance for local strategy planners in thoracic cancer care services in Mexico. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This article provides recommendations to guarantee the continuity of surgical care for thoracic oncology cases during COVID-19 pandemic, whilst maintaining the safety of patients and medical staff. WHAT THIS STUDY ADDS: This guideline is the result of an expert consensus on thoracic surgical oncology with recommendations adapted to medical, economic and social realities of Mexico.},
}

COVID-19/complications/*epidemiology/virology
Guidelines as Topic
Humans
Lung Neoplasms/complications/*epidemiology/surgery/virology
Medical Oncology/trends
Mexico/epidemiology
*Pandemics
SARS-CoV-2/pathogenicity
Thoracic Neoplasms/complications/*epidemiology/surgery/virology
Triage

@article {pmid32521580,
year = {2020},
author = {, and , },
title = {[Expert consensus on special blood purification technics in patients with corona virus disease 2019].},
journal = {Zhonghua nei ke za zhi},
volume = {59},
number = {11},
pages = {847-853},
doi = {10.3760/cma.j.cn112138-20200306-00202},
pmid = {32521580},
issn = {0578-1426},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; Coronavirus Infections/*blood ; *Hemofiltration ; *Hemoperfusion ; Humans ; Pandemics ; *Plasma Exchange ; Pneumonia, Viral/*blood ; SARS-CoV-2 ; },
abstract = {The outbreak of corona virus disease 2019 (COVID-19) has spread to more than 70 countries worldwide and there was a higher mortality in those who developed serious illness.Cytokine storm syndrome is an important pathophysiological basis for COVID-19 patients developing into severe or critical conditions. It was indicated in the diagnosis and treatment scheme, by the National Health Commission of the People's Republic of China, that blood purifications such as plasma exchange, plasma adsorption, hemoperfusion, hemofiltration and plasmafiltration could be considered for use in the critical patients with cytokine storm syndrome. This expert consensus, proposed by the Chinese Society of Nephrology and the Nephrology Committee of Chinese Research Hospital Association, is to guide and standardize the clinical application of blood purifications in the treatment of severe or critical patients with COVID-19.},
}

Betacoronavirus
COVID-19
China
Consensus
Coronavirus Infections/*blood
*Hemofiltration
*Hemoperfusion
Humans
Pandemics
*Plasma Exchange
Pneumonia, Viral/*blood
SARS-CoV-2

@article {pmid32358326,
year = {2020},
author = {Tang, PF and Hou, ZY and Wu, XB and Zhang, CQ and Wang, JW and Xing, X and Shao, ZW and Yu, AX and Wang, G and Chen, B and Zhang, P and Hu, YJ and Wang, BW and Guo, XD and Tang, X and Zhou, DS and Liu, F and Chen, AM and Zhang, K and Li, KN and Zhu, YB and , },
title = {Expert consensus on management principles of orthopedic emergency in the epidemic of coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {9},
pages = {1096-1098},
pmid = {32358326},
issn = {2542-5641},
mesh = {*Betacoronavirus ; COVID-19 ; Consensus ; *Coronavirus Infections/complications/epidemiology/prevention & control ; Epidemics ; Humans ; Minimally Invasive Surgical Procedures ; *Musculoskeletal Diseases/complications/therapy ; *Pandemics/prevention & control ; *Pneumonia, Viral/complications/epidemiology/prevention & control ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
Consensus
*Coronavirus Infections/complications/epidemiology/prevention & control
Epidemics
Humans
Minimally Invasive Surgical Procedures
*Musculoskeletal Diseases/complications/therapy
*Pandemics/prevention & control
*Pneumonia, Viral/complications/epidemiology/prevention & control
SARS-CoV-2

@article {pmid32307014,
year = {2020},
author = {Song, JC and Wang, G and Zhang, W and Zhang, Y and Li, WQ and Zhou, Z and , },
title = {Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.},
journal = {Military Medical Research},
volume = {7},
number = {1},
pages = {19},
pmid = {32307014},
issn = {2054-9369},
mesh = {Aged ; Anticoagulants/therapeutic use ; *Betacoronavirus ; Blood Coagulation Disorders/*diagnosis/drug therapy/virology ; COVID-19 ; China ; Consensus ; Coronavirus Infections/*complications ; Humans ; Middle Aged ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; },
abstract = {Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.},
}

Aged
Anticoagulants/therapeutic use
*Betacoronavirus
Blood Coagulation Disorders/*diagnosis/drug therapy/virology
COVID-19
China
Consensus
Coronavirus Infections/*complications
Humans
Middle Aged
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2

@article {pmid32295323,
year = {2020},
author = {, and , },
title = {[Expert consensus on sleep study and non-invasive positive airway pressure therapy during the epidemic of coronavirus disease 2019].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {6},
pages = {490-495},
doi = {10.3760/cma.j.cn112147-20200309-00283},
pmid = {32295323},
issn = {1001-0939},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; *Coronavirus ; Coronavirus Infections/epidemiology/*therapy ; Humans ; Noninvasive Ventilation/*methods ; Pandemics ; Pneumonia, Viral/epidemiology/*therapy ; Respiratory Insufficiency/*prevention & control ; SARS-CoV-2 ; Sleep/*physiology ; },
abstract = {Coronavirus disease (COVID-19) is mainly transmitted through respiratory droplets, close unprotected contact, and intense aerosols-generating procedures. Sleep study and non-invasive positive airway pressure (NIPAP) therapy can increase the risk of exposure and transmission of new coronaviruses to medical staff and patients. China's national epidemic control has entered a critical stage of overall prevention and control together with the restoration of normal medical care delivery. Based on the characteristics of sleep-disordered breathing, this consensus elaborates on the recommendations from the following four aspects that include patient and medical staff education, optimization of diagnostic and treatment protocols, sterilization of medical devices and the environment, and control of hospital-acquired infection. It is emphasized that the indications for sleep study and NIPAP should be strictly defined according to the local epidemic situation. Portable home sleep study and auto-titration positive airway pressure is recommended. The applications of disposable nasal pressure transducer for sleep study and disposable or personal masks and ventilator tubing for NIPAP are strongly suggested. Moreover, it is necessary to standardize the procedure of NIPAP, to separate the functional divisions in sleep lab, to comply with the protection regulations for medical personnel, and to strengthen the cleaning and disinfection management.},
}

Betacoronavirus
COVID-19
China
Consensus
*Coronavirus
Coronavirus Infections/epidemiology/*therapy
Humans
Noninvasive Ventilation/*methods
Pandemics
Pneumonia, Viral/epidemiology/*therapy
Respiratory Insufficiency/*prevention & control
SARS-CoV-2
Sleep/*physiology

@article {pmid32294813,
year = {2020},
author = {, },
title = {[Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {4},
pages = {288-296},
doi = {10.3760/cma.j.cn112147-20200304-00239},
pmid = {32294813},
issn = {1001-0939},
mesh = {Betacoronavirus ; Bronchoscopy ; COVID-19 ; Consensus ; Coronavirus Infections/*prevention & control/*therapy/transmission ; Critical Illness ; Cross Infection/*prevention & control/virology ; Filtration ; Humans ; Masks ; Pandemics/*prevention & control ; Pneumonia, Viral/*prevention & control/*therapy/transmission ; Respiratory Therapy/*standards ; SARS-CoV-2 ; Ventilators, Mechanical ; },
abstract = {Definite evidence has shown that the novel coronavirus (COVID-19) could be transmitted from person to person, so far more than 1 700 bedside clinicians have been infected. A lot of respiratory treatments for critically ill patients are deemed as high-risk factors for nosocomial transmission, such as intubation, manual ventilation by resuscitator, noninvasive ventilation, high-flow nasal cannula, bronchoscopy examination, suction and patient transportation, etc, due to its high possibility to cause or worsen the spread of the virus. As such, we developed this consensus recommendations on all those high-risk treatments, based on the current evidence as well as the resource limitation in some areas, with the aim to reduce the nosocomial transmission and optimize the treatment for the COVID-19 pneumonia patients. Those recommendations include: (1)Standard prevention and protection, and patient isolation; (2)Patient wearing mask during HFNC treatment; (3)Using dual limb ventilator with filters placed at the ventilator outlets, or using heat-moisture exchanger (HME) instead of heated humidification in single limb ventilator with HME placed between exhalation port and mask; avoid using mask with exhalation port on the mask; (4)Placing filter between resuscitator and mask or artificial airway; (5)For spontaneous breathing patients, placing mask for patients during bronchoscopy examination; for patients receiving noninvasive ventilation, using the special mask with bronchoscopy port to perform bronchoscopy; (6)Using sedation and paralytics during intubation, cuff pressure should be maintained between 25-30 cmH(2)O(1 cmH(2)O=0.098 kPa); (7)In-line suction catheter is recommended and it can be used for one week; (8)Dual-limb heated wire circuits are recommended and only changed with visible soiled; (9)For patients who need breathing support during transportation, placing an HME between ventilator and patient; (10)PSV is recommended for implementing spontaneous breathing trial (SBT), avoid using T-piece to do SBT. When tracheotomy patients are weaned from ventilator, HME should be used, avoid using T-piece or tracheostomy mask. (11)Avoid unnecessary bronchial hygiene therapy; (12) For patients who need aerosol therapy, dry powder inhaler metered dose inhaler with spacer is recommended for spontaneous breathing patients; while vibrating mesh nebulizer is recommended for ventilated patients and additional filter is recommended to be placed at the expiratory port of ventilation during nebulization.},
}

Betacoronavirus
Bronchoscopy
COVID-19
Consensus
Coronavirus Infections/*prevention & control/*therapy/transmission
Critical Illness
Cross Infection/*prevention & control/virology
Filtration
Humans
Masks
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control/*therapy/transmission
Respiratory Therapy/*standards
SARS-CoV-2
Ventilators, Mechanical

@article {pmid32268984,
year = {2020},
author = {He, Y and Wei, J and Bian, J and Guo, K and Lu, J and Mei, W and Ma, J and Xia, Z and Xu, M and Yan, F and Yu, C and Wang, E and Wang, W and Zeng, N and Wang, S and Xu, J and Huang, Y and Huang, J},
title = {Chinese Society of Anesthesiology Expert Consensus on Anesthetic Management of Cardiac Surgical Patients With Suspected or Confirmed Coronavirus Disease 2019.},
journal = {Journal of cardiothoracic and vascular anesthesia},
volume = {34},
number = {6},
pages = {1397-1401},
pmid = {32268984},
issn = {1532-8422},
mesh = {Anesthesiology/methods ; Anesthetics/*therapeutic use ; COVID-19 ; Cardiovascular Diseases/surgery/virology ; Cardiovascular Surgical Procedures ; Cardiovascular System/virology ; China/epidemiology ; *Consensus ; Coronavirus Infections/*drug therapy/epidemiology ; Disease Outbreaks ; Humans ; Pandemics ; Pneumonia, Viral/*drug therapy/epidemiology ; Practice Guidelines as Topic ; Renin-Angiotensin System/physiology ; },
abstract = {The outbreak of a new coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) in China in December 2019 has brought serious challenges to disease prevention and public health. Patients with severe coronavirus disease 2019 (COVID-19) who undergo cardiovascular surgery necessitate extremely high demands from anesthesia personnel, and face high risks of mortality and morbidity. Based on the current understanding of COVID-19 and the clinical characteristics of cardiovascular surgical patients, the authors provide anesthesia management guidelines for cardiovascular surgery along with the prevention and control of COVID-19.},
}

Anesthesiology/methods
Anesthetics/*therapeutic use
COVID-19
Cardiovascular Diseases/surgery/virology
Cardiovascular Surgical Procedures
Cardiovascular System/virology
China/epidemiology
*Consensus
Coronavirus Infections/*drug therapy/epidemiology
Disease Outbreaks
Humans
Pandemics
Pneumonia, Viral/*drug therapy/epidemiology
Practice Guidelines as Topic
Renin-Angiotensin System/physiology

@article {pmid32234175,
year = {2020},
author = {, and , },
title = {[Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19].},
journal = {Zhonghua xin xue guan bing za zhi},
volume = {48},
number = {3},
pages = {189-194},
doi = {10.3760/cma.j.cn112148-20200210-00066},
pmid = {32234175},
issn = {0253-3758},
mesh = {*Betacoronavirus ; COVID-19 ; *Cardiovascular Diseases/complications ; Consensus ; Coronavirus Infections/*complications/epidemiology ; Epidemics ; Humans ; Pandemics ; Pneumonia, Viral/*complications/epidemiology ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
*Cardiovascular Diseases/complications
Consensus
Coronavirus Infections/*complications/epidemiology
Epidemics
Humans
Pandemics
Pneumonia, Viral/*complications/epidemiology
SARS-CoV-2

@article {pmid32219814,
year = {2020},
author = {Specialized Committee Of Neurogenetics Neurophysician Branch Of Chinese Medical Doctor Association, and Jiang, H and Tang, B},
title = {[Expert consensus on the management strategy of patients with hereditary ataxia during prevention and control of novel coronavirus pneumonia epidemic].},
journal = {Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics},
volume = {37},
number = {4},
pages = {359-366},
doi = {10.3760/cma.j.issn.1003-9406.2020.04.001},
pmid = {32219814},
issn = {1003-9406},
mesh = {Betacoronavirus ; COVID-19 ; China/epidemiology ; Consensus ; Coronavirus Infections/complications/*epidemiology ; Epidemics ; Health Status ; Humans ; Mental Health ; Nervous System Diseases/virology ; Pandemics ; Pneumonia, Viral/complications/*epidemiology ; SARS-CoV-2 ; *Spinocerebellar Degenerations/complications/diagnosis/prevention & control/therapy ; },
abstract = {Since December 2019, a series of highly infectious cases of unexplained pneumonia have been discovered in Wuhan, Hubei Province, which have been confirmed as '2019 corona virus disease' caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 virus can invade many human systems including the lungs. Patients with central nervous system involvement may show a series of neurological symptoms, which is easy to be misdiagnosed and neglected, thereby increasing the risk of SARS-CoV-2 transmission. Hereditary ataxia is a large group of neurodegenerative diseases with great clinical and genetic heterogeneity and high mortality and disability. In view of the seriousness of the COVID-19 epidemic, a series of prevention and control measures adopted by the government have restricted the follow-up, diagnosis and treatment of patients by the hospitals, which has a great impact on their mental and physical health. In order to standardize the management of patients during the prevention and control of COVID-19 epidemic, the Specialized Committee of Neurogenetics of the Neurophysician Branch of Chinese Medical Doctor Association has formulated this consensus, with an aim to help patients to overcome the difficulties and pass the epidemic prevention period safely.},
}

Betacoronavirus
COVID-19
China/epidemiology
Consensus
Coronavirus Infections/complications/*epidemiology
Epidemics
Health Status
Humans
Mental Health
Nervous System Diseases/virology
Pandemics
Pneumonia, Viral/complications/*epidemiology
SARS-CoV-2
*Spinocerebellar Degenerations/complications/diagnosis/prevention & control/therapy

@article {pmid32164085,
year = {2020},
author = {, },
title = {[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {3},
pages = {185-188},
doi = {10.3760/cma.j.issn.1001-0939.2020.03.009},
pmid = {32164085},
issn = {1001-0939},
support = {2020B111113001//Emergency program for major public health event of Ministry of Science and Technology, Department of Science and Technology of Guangdong Province/ ; 2020GZR110106003//Guangzhou Regenerative Medicine and Health Guangdong Laboratory: Evaluation of clinical efficacy of chloroquine on 2019 novel coronavirus pneumonia/ ; },
mesh = {Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage ; COVID-19 ; China ; Chloroquine/administration & dosage/*analogs & derivatives ; Consensus ; Coronavirus Infections/*complications ; Drug Administration Schedule ; Humans ; Length of Stay ; Pneumonia, Viral/*complications/drug therapy/etiology ; Practice Guidelines as Topic ; },
abstract = {At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.},
}

Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
COVID-19
China
Chloroquine/administration & dosage/*analogs & derivatives
Consensus
Coronavirus Infections/*complications
Drug Administration Schedule
Humans
Length of Stay
Pneumonia, Viral/*complications/drug therapy/etiology
Practice Guidelines as Topic

@article {pmid32164084,
year = {2020},
author = {Zhao, JP and Hu, Y and Du, RH and Chen, ZS and Jin, Y and Zhou, M and Zhang, J and Qu, JM and Cao, B},
title = {[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {3},
pages = {183-184},
doi = {10.3760/cma.j.issn.1001-0939.2020.03.008},
pmid = {32164084},
issn = {1001-0939},
mesh = {Adrenal Cortex Hormones/*therapeutic use ; *Betacoronavirus ; COVID-19 ; Consensus ; Coronavirus Infections/*drug therapy ; Humans ; Pneumonia, Viral/*drug therapy ; SARS-CoV-2 ; COVID-19 Drug Treatment ; },
}

Adrenal Cortex Hormones/*therapeutic use
*Betacoronavirus
COVID-19
Consensus
Coronavirus Infections/*drug therapy
Humans
Pneumonia, Viral/*drug therapy
SARS-CoV-2
COVID-19 Drug Treatment

@article {pmid32129580,
year = {2020},
author = {, and , },
title = {[Expert consensus on pulmonary function testing during the epidemic of coronavirus disease 2019].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {4},
pages = {302-307},
doi = {10.3760/cma.j.cn112147-20200225-00175},
pmid = {32129580},
issn = {1001-0939},
support = {2018YFC1311900, 2016YFC1304603//National Key Research and Develop Program of China/ ; 2015BAI12B10//National Science and Technology Support Plan/ ; },
mesh = {Betacoronavirus ; COVID-19 ; Consensus ; Coronavirus Infections/*prevention & control ; Disinfection ; Humans ; Infection Control/*methods ; Pandemics/*prevention & control ; Pneumonia, Viral/*prevention & control ; Respiratory Function Tests/*standards ; SARS-CoV-2 ; },
abstract = {Coronavirus disease 2019 (COVID-19) is transmitted mainly by respiratory droplets and close contact, probably by aerosol. Pulmonary function testing procedures have been associated with an increasing risk of COVID-19 transmission among patients/subjects and medical staffs. Effective prevention and control strategies must be compulsorily implemented to prevent nosocomial infection. This recommendation is intended to be followed by healthcare workers (HCWs) of pulmonary function testing laboratory when COVID-19 is in epidemic. Based on the features of pulmonary function testing, precaution principles and considerations are developed in three aspects of management for HCWs, operating procedure, environment and equipment. Indications of pulmonary function testing should be followed strictly. It is strongly recommended to suspend the test for the confirmed or suspected cases of COVID-19 during the contagious stage, and to postpone the test for other patients if it is not imperative. Medical personnel should mandatorily adhere to the standard stratification of precaution measures. Patients/Subjects should be isolated in a separate area for testing. Disposable in-line filters must be used during pulmonary function testing. Cleaning and disinfection procedures for environment and equipment in pulmonary function testing laboratory should be paid more attention.},
}

Betacoronavirus
COVID-19
Consensus
Coronavirus Infections/*prevention & control
Disinfection
Humans
Infection Control/*methods
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Respiratory Function Tests/*standards
SARS-CoV-2

@article {pmid32028773,
year = {2020},
author = {, },
title = {Fighting the novel coronavirus: the publication of the Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition).},
journal = {Annals of palliative medicine},
volume = {9},
number = {2},
pages = {524-525},
doi = {10.21037/apm.2020.02.02},
pmid = {32028773},
issn = {2224-5839},
mesh = {Betacoronavirus ; COVID-19 ; China ; *Consensus ; Coronavirus Infections/*prevention & control/therapy ; Female ; Humans ; Infant Care/standards ; Infant Welfare/*prevention & control ; Infant, Newborn ; Mass Screening/standards ; Pandemics/*prevention & control ; Perinatal Care/*standards ; Pneumonia, Viral/*prevention & control/therapy ; Practice Guidelines as Topic ; Pregnancy ; SARS-CoV-2 ; },
}

Betacoronavirus
COVID-19
China
*Consensus
Coronavirus Infections/*prevention & control/therapy
Female
Humans
Infant Care/standards
Infant Welfare/*prevention & control
Infant, Newborn
Mass Screening/standards
Pandemics/*prevention & control
Perinatal Care/*standards
Pneumonia, Viral/*prevention & control/therapy
Practice Guidelines as Topic
Pregnancy
SARS-CoV-2